Stockwinners Market Radar for October 03, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EDT Cathie Wood's ARK Investment bought 201K shares of Roblox today

19:34 EDT Alphabet exec sells $3.48M in common stock - In a regulatory filing, Alphabet disclosed that its Global Affairs President John Walker sold 34.8K shares of common stock on September 28th in a total transaction size of $3.48M.

18:49 EDT NYSE American to suspend trading immediately in Ampio, start delisting process - NYSE American announced earlier that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Ampio Pharmaceuticals - ticker symbol AMPE - from the Exchange. Trading in the company's common stock on the NYSE American will be suspended immediately. NYSE Regulation has determined that the company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the abnormally low trading price of its common stock. The company has a right to a review of staff's determination to delist the common stock by a committee of the board of directors of the Exchange. The NYSE American will apply to the Securities and Exchange Commission to delist the company's common stock upon completion of all applicable procedures, including any appeal by the company of the NYSE Regulation staff's decision.

18:44 EDT American Homes 4 Rent says damage from Hurricane Ian 'limited' - The company states: "American Homes 4 Rent announced that, based on its preliminary assessments, the Company suffered limited damage from Hurricane Ian to its single-family homes and communities located in Florida, Georgia, South Carolina and North Carolina. The Company will continue to assess its portfolio and provide additional information or updates in the event of a material change in this situation."

18:27 EDT Kura Sushi names Jeff Uttz as new CFO - Kura Sushi "announced that Jeff Uttz has been named the Company's new Chief Financial Officer, effective October 3, 2022."

17:47 EDT AnPac Bio names Haohan Xu co-chair, co-CEO - AnPac Bio-Medical Science announced changes to its board composition and management team. Haohan Xu has been appointed as a director of the board of directors, Co-Chairperson of the Board and Co-Chief Executive Officer of the company. Xu is the Chief Executive Officer of Apifiny Group. Xiaoyu Li has been appointed as a director of the Board and as Chief Financial Officer of the company. In relation to the above appointments, each of Mr. Chris Chang Yu, Jinqiu Tang, Xing Pu, Ren Luo, Jianhua Shao and Guo Feng will resign as a director and/or officer of the Company. These changes are expected to become effective in early October after the completion of customary onboarding processes, including required filings with The Registry of Corporate Affairs in the British Virgin Islands.

17:37 EDT General Dynamics awarded $532.92M Navy contract modification - General Dynamics was awarded a $532.92M cost-plus-fixed-fee modification to previously awarded contract for Lead Yard Support and Development Studies and Design efforts related to Virginia-class submarines. This contract modification includes options which, if exercised, would bring the cumulative value of the modification to $813.72M. Work is expected to be completed by October 2023. The Naval Sea Systems Command is the contracting activity.

17:36 EDT Lockheed Martin awarded on $5.1B Navy contract modifications - Lockheed Martin and others were awarded an estimated aggregate ceiling of $5.1B for firm-fixed-price modifications to a previously awarded indefinite-delivery/indefinite-quantity contract. These modifications exercise options for the production and delivery of the following sonobuoy capability categories: bathythermograph, passive, active/passive combo, multistatic source, multistatic receiver, and special mission in support of annual training, peacetime operations and testing expenditures, as well as, to maintain sufficient inventory to support the execution of Major Combat Operations based on Naval Munitions Requirements Process. The companies have an opportunity to compete for individual orders. Work is expected to be completed in September 2027. No funds will be obligated at the time of award. Funds will be obligated on individual orders as they are issued. The Naval Air Systems Command is the contracting activity.

17:28 EDT General Mills exec sells $2.0M in common stock - In a regulatory filing, General Mills disclosed that its Group President Jonathon Nudi sold 25.9K shares of common stock on September 30th in a total transaction size of $2.01M.

17:04 EDT Ferroglobe plans to restart 55K ton silicon metal facility in South Africa - Ferroglobe announces the intention to restart its 55,000-ton silicon metal facility in Polokwane, South Africa. The decision to restart the Polokwane facility was made as part of Ferroglobe's strategic plan to increase its capacity of silicon metal to address strong market demand. The Polokwane plant will enable the Company to add capacity that is lower cost and strategically located, optimizing its asset footprint, and providing flexibility in addressing the volatile energy markets in Europe. The Polokwane facility provides a lower-cost source of silicon metal that is driven by competitive energy rates, an efficient asset base and a strategic location that can serve customers in Europe, the United States, the Middle East and Asia. The decision to restart this plant was contingent on the Company's ability to secure multi-year contracts with strategic customers, which are currently being finalized. Ferroglobe expects to begin production of the three-furnace operation in November 2022, with initial production of approximately 1,150 metric tons per month, gradually ramping up to approximately 3,750 metric tons per month by the end of Q2 2023. Marco Levi, Ferroglobe's Chief Executive Officer commented, "Our Polokwane facility is a key part of our global asset footprint that allows us the flexibility to serve customers efficiently and effectively around the world. It is a lower-cost facility that is strategically important as we optimize our production geographically in response to the energy crises in Europe."

17:02 EDT Mereo confirms receipt of notice from Rubric to convene shareholder meeting - Mereo BioPharma Group confirmed that it has received a valid notice from Rubric Capital Management LP under section 303 of the Companies Act 2006 requiring the Board to convene a General Meeting of Shareholders of Mereo. The Board believes Rubric's resolutions - which, if passed, would replace a majority of the independent directors of the Board with Rubric's hand-picked candidates - would constitute an effective takeover of Mereo's Board, substantially weakening it and jeopardizing the company's considered efforts to generate maximum risk-adjusted returns from its programs and assets. "Prior to receiving a valid notice from Rubric, in an attempt to minimize disruption and expense, Mereo responded to Rubric's proposal to nominate four directors, which was contained in Rubric's previous invalid notices, by offering to put one of Rubric's principals and a second new, fully independent candidate on its Board, as a compromise to Rubric's overreaching demands," the company said. "Rubric declined this reasonable offer, refused to make any counteroffer and responded today with an escalated proposal that now nominates five directors, seeking to control the Board and the Company's future strategy through its resolutions. The Board urges Mereo shareholders to reject all Rubric's resolutions at the General Meeting."

16:56 EDT Rocket Pharmaceuticals drops 6% to $14.49 after $100M common stock offering

16:47 EDT AeroClean jumps 38% to $4.43 after announcing merger with Molekule

16:39 EDT Mosaic 'negatively impacted' by Hurricane Ian damage - The Mosaic Company announced that North American Phosphates was negatively impacted by damage caused by Hurricane Ian. Significant flooding and high winds were experienced throughout central Florida during the storm, and this caused modest damage to the company's facilities and to supporting infrastructure. As a result, early assessments indicate phosphate production could be down by approximately 200,000-250,000 tonnes, split roughly evenly between the third and fourth quarters of 2022. Repairs are expected to be completed over the next 1-2 weeks. In addition to production impacts, the timing of shipments was also affected by the storm. Phosphates sales volumes in Q3 are now expected to total 1.60M-1.65M tonnes, as port and rail closures delayed late Q3 shipments to October. Mosaic plans to provide further updates when it reports Q3 results.

16:37 EDT Rivian Automotive produces 7,363 vehicles in Q3 - Rivian Automotive, Inc. announced production totals for the quarter ending September 30, 2022. The company produced 7,363 vehicles at its manufacturing facility in Normal, Illinois and delivered 6,584 vehicles during the same period. These figures remain in line with the company's expectations, and it believes it is on track to deliver on the 25,000 annual production guidance previously provided.

16:35 EDT Oncternal Therapeutics receives 'Study May Proceed' letter from FDA for ONCT-808 - Oncternal Therapeutics announced the receipt of a 'Study May Proceed' letter from the FDA, 30 days after submitting its Investigational New Drug, or IND, application for a Phase 1/2 dose escalation study of ONCT-808, an autologous chimeric antigen receptor, or CAR, T therapy targeting ROR1, in patients with aggressive B cell non-Hodgkin's lymphoma (B NHL), including those who have failed previous CD19 CAR T treatment.

16:33 EDT Vapotherm receives NYSE continued listing standard notice - Vapotherm announced that it was notified on September 27, 2022 by the New York Stock Exchange that the company is not in compliance with the NYSE's continued listing standards as a result of the company's average market capitalization being less than $50M over a consecutive 30 trading-day period and the most recently reported stockholders' equity of the company also being less than $50M.

16:31 EDT PennyMac Financial names Jerry Halbrook as Chief Mortgage Innovation Officer - PennyMac Financial "announced the appointment of Jerry Halbrook as the organization's Chief Mortgage Innovation Officer. With decades of Fintech experience, Mr. Halbrook will develop and launch new technology solutions, preparing the company for future innovations while enhancing Pennymac's business model."

16:26 EDT BMW of North America reports Q3 BMW brand sales in U.S. up 3.2% y/y - BMW of North America reported Q3 2022 sales results for the BMW and MINI brands in the U.S. In the third quarter of 2022, BMW brand sales in the U.S. totaled 78,031 vehicles, a 3.2% increase from the 75,619 vehicles sold in the third quarter of 2021. MINI brand sales in the U.S. totaled 7,178 vehicles in the third quarter of 2022, an increase of 11.4% vs the 6,445 vehicles sold in the third quarter of 2021.

16:20 EDT Enhabit acquires Caring Hearts Hospice, terms not disclosed - Enhabit announced the acquisition of Caring Hearts Hospice, a locally owned and operated hospice agency in Texas. Effective Oct. 1, 2022, this acquisition adds four hospice locations to Enhabit's existing presence in Texas, allowing Enhabit to expand its nationwide footprint. "We are excited to welcome the Caring Hearts Hospice employees to Enhabit," says Enhabit President and CEO Barb Jacobsmeyer. "Their passion for and dedication to providing high-quality care to patients and their loved ones is a perfect fit for our team as we continue to expand our hospice service line." With the transaction, Enhabit will now have a presence in Gun Barrel City, Mineola, Palestine, and Quinlan, Texas. Enhabit is the fourth largest provider of Medicare-certified home health services and the 12th largest provider of Medicare-certified hospice services nationally.

16:19 EDT Essex Property Trust CEO Michael Schall to retire - Essex Property Trust "announced the planned retirement of Michael J. Schall, the Company's President and CEO since 2011, effective March 31, 2023. Thereafter, Mr. Schall will continue to serve on the Company's Board of Directors and will remain on as a part-time employee. The Board of Directors has appointed Angela L. Kleiman, the Company's Senior Executive Vice President and Chief Operating Officer, to succeed Mr. Schall as President and CEO."

16:18 EDT Akanda receives Nasdaq notification regarding minimum bid price deficiency - Akanda Corp. announced that the company has received a written notification on September 27, 2022 from the Listing Qualifications Department of the Nasdaq Stock Market LLC, notifying the company that it is not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the company's common shares, no par value, was below $1.00 per share for a period of 30 consecutive business days. The Notification Letter does not impact the Company's listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the company has been provided 180 calendar days, or until March 27, 2023, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the company's common shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by March 27, 2023, the Company may be eligible for additional time to regain compliance or may face delisting.

16:17 EDT CACI CFO Mutryn to retire - CACI International announced that Executive Vice President Thomas A. Mutryn will retire as the company's Chief Financial Officer and Treasurer after more than 16 years of service. Effective November 1, 2022, Jeffrey (Jeff) D. MacLauchlan will assume the role of EVP, CFO, and Treasurer of CACI as a named executive officer. Mutryn will continue in his role as an EVP to assist with the transition until his retirement date on January 9, 2023. "It has been my great pleasure to work with Tom over the last decade," said CACI President and Chief Executive Officer (CEO) John Mengucci. "Tom's numerous contributions include successfully leading our finance organization, implementing sound organic and inorganic growth strategies, fostering relationships with the investor and analyst communities, as well as providing leadership for a number of years of our discriminating Mergers & Acquisition (M&A) program."

16:17 EDT American Tower EVP/General Counsel Ed DiSanto to step down - American Tower "announced changes to its senior management team. Ed DiSanto intends to step down from his position as Executive Vice President, Chief Administrative Officer, General Counsel and Secretary, effective January 1, 2023. Ruth Dowling, who has been with American Tower for over ten years, will succeed Mr. DiSanto in the role of Executive Vice President, Chief Administrative Officer, General Counsel and Secretary, effective January 1, 2023. To assist in the transition of responsibilities, Mr. DiSanto will assume the new role of Executive Vice President, Special Advisor and Counsel to the Chief Executive Officer, reporting to Tom Bartlett, effective January 1, 2023."

16:16 EDT Utz Brands CEO Lissette to become executive chairman - Utz Brands announced that, after 27 years with the company, Dylan Lissette, currently Chief Executive Officer, will be appointed Executive Chairman of the Board, effective December 15, 2022. At that time, Howard Friedman, currently Chief Operations Officer of Post Holdings, Inc., will join the Company as Chief Executive Officer and serve as a member of the Utz Board. Commensurate with these appointments, Roger Deromedi, current Chairman of the Board, will become Lead Independent Director. Lissette will transition to the role of Non-Executive Chairman of the Board in the second quarter of 2023. This leadership transition was initially contemplated at the time of the merger between Collier Creek Holdings and Utz and is a natural next step as Utz continues to develop as a public company. The search for the next CEO of Utz included the consideration of both internal and external candidates, leading to the identification of Friedman as an ideal successor to Lissette, with the right CPG experience and expertise to lead the company as it accelerates its proven growth strategy, the company said.

16:14 EDT BlueLinx sees Vandermeer acquisition as immediately accretive to diluted EPS - The purchase of Vandermeer was funded through cash on hand and is expected to be immediately accretive to diluted earnings per share on a pre-synergy basis. BlueLinx intends to optimize its treatment of the transaction by making a 338(h)(10) tax election. After funding the acquisition, BlueLinx's net leverage did not materially change and the company continues to have ample liquidity through a combination of cash on hand and availability under its undrawn revolving credit facility.

16:12 EDT First Financial Northwest announces 5% share repurchase program - First Financial Northwest announced that its board of directors has authorized the repurchase of up to 5% of the company's outstanding common stock, or approximately 456,000 shares, on the open market or in privately negotiated transactions, in accordance with Rule 10b-18 of the Securities Exchange Act of 1934. The new stock repurchase plan will commence on or about October 31 and will expire no later than March 17, 2023. The extent to which the company repurchases its shares and the timing of such repurchases will depend upon market conditions and other corporate considerations. As a result, there can be no assurance as to the exact number of shares, if any, that will be repurchased under the plan.

16:11 EDT Marvell CEO Carl Hull to switch roles, William Martin to succeed - Maravai (MRVL) announced that its board of directors has appointed William Martin, III as its chief executive officer, or CEO. Martin comes to Maravai most recently from Danaher (DHR), where he was the senior VP of new business, genomic medicine. Maravai's first CEO and co-founder Carl Hull will directly support Martin during this leadership transition and will remain with Maravai as executive chairman of the board where he will continue to guide the company's long-term strategy. Hull will remain involved with the strategic direction of Maravai as the executive chairman of the board and will work together with Martin. The company will further discuss the management transition plan on its third quarter earnings call currently scheduled for November 2.

16:10 EDT AeroClean Technologies Inc trading halted, news pending

16:08 EDT SWK Holdings names Yvette Heinrichson as CFO, succeeding Charles Jacobson - SWK Holdings announced that the company has promoted Yvette Heinrichson to the role of CFO. Heinrichson was previously SWK's Chief Accounting Officer. SWK has also promoted John David Tamas to Director of Underwriting, a newly created position at the company, and has hired Joe Moyer as an Associate. As CFO, Heinrichson will lead SWK's financial reporting and accounting activities as well as assist President and Interim CEO, Jody Staggs, with capital markets initiatives. Heinrichson replaces Charles Jacobson, who held the position of CFO on an outsourced basis since 2012.

16:06 EDT Bank OZK boosts dividend to 33c per share up 3.13% - Bank OZK announced its Board of Directors declared a quarterly cash dividend on the Bank's common stock of 33c per share, up 1c, or 3.13% from the prior quarter. The common stock dividend is payable on October 21, to shareholders of record as of October 14 . Bank OZK has increased its quarterly cash dividend on its common stock in each of the last forty-nine quarters.

16:06 EDT Bank OZK boosts dividend to 33c per share up 3.13% - Bank OZK announced its Board of Directors declared a quarterly cash dividend on the Bank's common stock of 33c per share, up 1c, or 3.13% from the prior quarter. The common stock dividend is payable on October 21, to shareholders of record as of October 14 . Bank OZK has increased its quarterly cash dividend on its common stock in each of the last forty-nine quarters.

16:06 EDT Olin announces chlorinated organics capacity reduction - Olin announced that it expects to cease methylene chloride and chloroform production at its Stade, Germany facility by third quarter 2023. Olin will continue to produce both products at its Freeport, Texas facility.

16:06 EDT Addus HomeCare acquires Apple Home Healthcare - Addus HomeCare "announced the acquisition of Apple Home Healthcare, LTD, effective October 1, 2022. Based in Chicago, Illinois, Apple serves an average daily adult census of approximately 450 patients in an 11-county metro area in and around Chicago, with annual revenues of approximately $10M. Founded 25 years ago, Apple offers home health services for patients recovering from acute illnesses and procedures. Addus funded the acquisition through a combination of cash on hand and the Company's revolving credit facility and is expected to be immediately accretive to financial results."

16:03 EDT Manitowoc expands DTC footprint in Colorado, Wyoming, Nebraska - The Manitowoc Company announced that through its wholly-owned subsidiary, MGX Equipment Services, LLC, it has completed the acquisition of certain assets of the crane rental fleet of Honnen Equipment Company. Under the agreement Honnen ends its dealer agreement with Manitowoc in Colorado, Wyoming, and Nebraska. The transaction expands Manitowoc's direct-to-customer footprint in the territory with new sales, used sales, aftermarket parts, and service support to a variety of end market customers.

15:45 EDT VP of Dollar General Wenkoff sold 10,000 shares of company stock - VP of Dollar General Carman Wenkoff sold 10,000 shares of company stock for $240.49 per share, on September 30, for a total transaction amount of $2,404,911.

14:17 EDT Nissan reports Q3 U.S. sales down 22.6% to 154,086 units - Nissan Group announced total U.S. third-quarter sales for 2022 of 154,086 units, a decrease of 22.6% versus the prior year. Nissan Division sales were down 24.1% to 142,845 units while Infiniti Division sales were up 5.4% to 11,241 units. Reference Link

14:13 EDT Volkswagen of America reports Q3 sales up 12% to 88,820 vehicles - Volkswagen of America reported Q3 sales of 88,820 vehicles, up 12.0% from last year. Year-to-date, its sales of 232,099 vehicles are down 20.1% relative to 2021.

13:56 EDT Amazon launches Amazon Access for more affordable shopping options - Amazon introduced Amazon Access, a one-stop-shop for customers to explore programs, discounts, and features that make shopping on Amazon "even easier and more affordable." Here, customers will find information on options like payment with SNAP EBT, Amazon Layaway, and more, the company said. Key among the programs featured in the hub is Prime Access, Prime's discounted membership program for qualifying government assistance recipients. Eligible customers in the U.S. who sign up for Prime Access get all the exclusive benefits and perks of a Prime membership for just $6.99 a month-more than 50% off the cost of a full-priced membership. "Given the tough economic climate, with many facing rising costs on essential needs, we want our customers to know about all the accessible offerings available on Amazon, no matter their circumstances," Amazon said. Reference Link

13:20 EDT Twitter says Edit Tweet feature 'coming soon' to U.S. - Twitter Blue tweeted: "test went well, Edit Tweet is now rolling out to Twitter Blue members in Canada, Australia, and New Zealand! US coming soon" Reference Link

13:02 EDT Pfizer completes acquisition of Biohaven Pharmaceutical - Pfizer (PFE) announced the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd. (BHVN), the maker of NURTEC ODT, a migraine therapy approved for both acute treatment and prevention of episodic migraine in adults. "We are proud to build on Pfizer's legacy of delivering breakthrough medicines for patients living with complex pain disorders," said Aamir Malik, Executive Vice President, Chief Business Innovation Officer, Pfizer. Pfizer acquired all of the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, for a total transaction consideration of approximately $11.6B. As a result of the acquisition, Biohaven became a wholly-owned subsidiary of Pfizer. Effective immediately prior to the closing of the acquisition, Biohaven completed the spin-off of Biohaven Ltd., distributing Biohaven Ltd.'s shares to Biohaven's shareholders. Biohaven Ltd., a new company that retained Biohaven's non-CGRP development stage pipeline compounds, holds the Kv7 ion channel activators, glutamate modulation, and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure assets excluded from the Pfizer acquisition. Pfizer, a Biohaven shareholder, received a pro rata portion of Biohaven Ltd.'s shares in the distribution and owns approximately 3% of Biohaven Ltd. Biohaven Ltd. will continue to trade on the New York Stock Exchange under the ticker "BHVN".

13:01 EDT Rockwell Automation appoints Robin Saitz as CMO - Rockwell Automation announced that Robin Saitz has been promoted to vice president, Global Marketing and Chief Marketing Officer. She reports to Scott Genereux, senior vice president and Chief Revenue Officer. In her new role, Saitz has global responsibility to lead marketing of Rockwell's full portfolio. With a focus on driving demand and building the brand globally, she oversees industry strategy, marketing communications, analyst relations, demand generation, and commercial marketing. Saitz joined Rockwell as part of the company's acquisition of Plex Systems, completed in September 2021. Most recently, Robin led marketing for software as a service in Rockwell's Software & Control business segment as the Plex & Fiix Chief Marketing Officer. Fiix was acquired by Rockwell in January 2021. The SaaS and Rockwell marketing teams will come together under Saitz's leadership.

12:42 EDT Interactive Brokers reports September DARTs down 13% y/y - Interactive Brokers Group reported its Electronic Brokerage monthly performance metrics for September. Brokerage highlights for the month included: 1.961 million Daily Average Revenue Trades, 13% lower than prior year and about even with prior month. Ending client equity of $287.1B, 19% lower than prior year and 7% lower than prior month. Ending client margin loan balances of $40.5B, 19% lower than prior year and 6% lower than prior month. Ending client credit balances of $94.7B, including $2.3B in insured bank deposit sweeps, 10% higher than prior year and 1% lower than prior month. 2.01 million client accounts, 31% higher than prior year and 1% higher than prior month. 221 annualized average cleared DARTs per client account. Average commission per cleared Commissionable Order of $3.05 including exchange, clearing and regulatory fees.

12:31 EDT Richardson Electronics announces new patent pending Ultravoltage3000 - Richardson Electronics announced a new product adding to its portfolio of green energy solutions. The company said: "The new ULTRAVOLTAGE3000 is a voltage discharge tool used for removing stored energy in ultracapacitors. Based on customers' needs, the ULTRAVOLTAGE3000 removes stored energy within various ultracapacitor applications, allowing technicians to work in otherwise hazardous enclosures without the risk of releasing stored energy or electrical energy shock."

12:00 EDT Hippo falls -10.8% - Hippo is down -10.8%, or -$2.00 to $16.54.

12:00 EDT LiveWire rises 20.2% - LiveWire is up 20.2%, or $1.45 to $8.63.

12:00 EDT Myovant Sciences rises 37.9% - Myovant Sciences is up 37.9%, or $6.81 to $24.77.

11:08 EDT General Motors reports U.S. Q3 sales up 24% to 555,580 vehicles - General Motors announced it sold 555,580 vehicles in the United States in the third quarter, up 24% year over year, based on "strong customer demand and improved availability." The company added: "Three of GM's vehicle brands posted double-digit total sales gains, with Chevrolet up 30%, GMC up 24% and Cadillac up 50%. GM and its dealers were able to translate improved semiconductor supplies, stable production and improvements in dealer inventory into a nearly 3-point improvement in retail market share year over year, as well as significant sales gains in the commercial fleet market." GM reported "record" quarterly sales of the Chevrolet Bolt EV and Bolt EUV, which totaled 14,709 units combined. "In response to unprecedented customer demand, GM plans to increase calendar-year production for global markets from approximately 44,000 vehicles in 2022 to more than 70,000 in 2023," GM said.

10:46 EDT Vuzix, Hodei Technology partner for Klabra platform - Vuzix announced that it has received and shipped against an initial volume purchase order from Hodei Technology, an Indiana-based developer and seller of secure, enterprise collaboration solutions designed for a global, connected, and remote workforce, to support the company's newly launched Klabra platform.

10:30 EDT BurgerFi says no locations sustained significant damage from Hurricane Ian - In continued assessment of the impact from Hurricane Ian, BurgerFi International is working with its team members, guests, and regional partners in the coming days to help support with recovery efforts in the community. Currently, 174 of the 178 BurgerFi and Anthony's Coal Fired Pizza & Wings locations are fully operational and serving our local communities. None of our locations sustained significant damage, and we expect the two franchised and two corporate-owned BurgerFi locations that are temporarily out of power to open shortly after it is restored.

10:23 EDT Community Heritage announces data security incident - Community Heritage Financial announced that on October 1, 2022, the Bank determined there was unauthorized access to a portion of its information technology system. The company said, "Within hours of the detection of the event, the Bank implemented a series of containment and remediation measures to address the situation. The Bank also launched an investigation and engaged legal counsel, a computer forensic firm and other incident response professionals. Although we are continuing to assess the situation, at this time we do not believe that any customer information was accessed. In addition, based on the information currently known to us, at this time we do not believe that the incident will have a material impact on our business or operations, and we expect our branches to continue to operate in the normal course of business."

10:01 EDT Chris Stigall signs multi-year extension with Philadelphia's AM 990 - Salem Media Group announced today Chris Stigall has signed a multi-year extension to remain with Philadelphia's AM 990, The Answer as host of "Philadelphia's Morning Answer with Chris Stigall".

10:00 EDT Enfusion falls -11.0% - Enfusion is down -11.0%, or -$1.35 to $10.98.

10:00 EDT LiveWire rises 15.3% - LiveWire is up 15.3%, or $1.10 to $8.28.

10:00 EDT Myovant Sciences rises 35.3% - Myovant Sciences is up 35.3%, or $6.34 to $24.30.

09:47 EDT Marine Products falls -7.7% - Marine Products is down -7.7%, or -65c to $7.81.

09:47 EDT Blue Apron falls -19.7% - Blue Apron is down -19.7%, or -$1.14 to $4.64.

09:47 EDT Myovant Sciences rises 31.1% - Myovant Sciences is up 31.1%, or $5.59 to $23.55.

09:46 EDT Maris-Tech receives court's approval for up to $1M in share repurchases - Maris-Tech Ltd. announced that on September 30, 2022, it received approval from the Israeli court for its previously announced share repurchase plan, allowing the company to use up to $1M to repurchase its ordinary shares, no par value. The approval is valid until March 31, 2023. If the company has not reached the maximum amount under the Repurchase Plan on or before March 31, 2023, it will be required to seek additional approval from the Israeli court to continue the Repurchase Plan. The Repurchase Plan does not obligate the company to repurchase any specific number of the Ordinary Shares and may be suspended or terminated at any time at management's discretion.

09:43 EDT Colliers International establishes automatic share purchase plan - Colliers International announced that it has established an automatic share purchase plan in connection with its previously announced normal course issuer bid applicable to its outstanding subordinate voting shares. The automatic share purchase plan is intended to allow for the purchase of subordinate voting shares under the NCIB at times when Colliers would ordinarily not be permitted to purchase its securities due to regulatory restrictions and customary self-imposed blackout periods. The ASPP has been pre-cleared by the TSX and will be implemented beginning on October 3 and, if not terminated sooner based on the terms of the ASPP, will terminate on October 28.

09:38 EDT Hilton to feature Peloton Bikes across entire U.S. hotel portfolio - Earlier today, Hilton (HLT) and Peloton Interactive (PTON) announced what the companies called "an industry-first partnership" that will make Hilton the first hospitality brand to feature Peloton Bikes across its entire U.S. hotel portfolio of 18 brands. "By the end of the year, nearly all 5,400 U.S. Hilton-branded hotels - from Hampton by Hilton to Waldorf Astoria - will feature at least one Peloton Bike in every fitness center, providing guests with a more holistic wellness experience, including access to Peloton's world-class instructors and expansive connected fitness content," the companies stated. Matt Schuyler, chief brand officer, Hilton, added: "This unique and exciting partnership with Peloton - a brand so many of our guests know and love - accelerates an important part of that equation, allowing us to enhance the stay with an innovative approach to fitness." In early trading following the news, Peloton shares are down 11c, about 2%, to $6.82.

09:32 EDT Kiwa Bio-Tech Products stockholders sign cooperation agreement with Xiaoman - On October 3, 2022, the company issued an 8K announcement, disclosing that on September 25, 2022, the Preferred Stockholders of the company signed a cooperation agreement with a BVI-registered Xiaoman International Holdings Co., Ltd. Xiaoman will assist the company in completing important tasks such as annual report auditing and asset restructuring. Pursuant to the Cooperation Agreement, Xiaoman will assist the Company in seeking potential acquisition targets in digital assets, digital collections, film and television culture, Metaverse and other fields and eventually listing the Company on a national exchange. The Preferred Stockholders agreed to vote for the director nominees by Xiaoman and acquisition transactions Xiaoman may propose in board meetings and shareholder meetings.

09:31 EDT Boeing reports U.S. Army order for two more CH-47F Block II Chinooks - The U.S. Army is "continuing to modernize its heavy-lift helicopter fleet" with an order for two more Boeing CH-47F Block II Chinooks and long lead funding for additional aircraft, the company announced. "Last year, the Army awarded Boeing a $136 million contract for the first four CH-47F Block II aircraft, which began production in April 2022. The Lot 2 order valued at $63M brings the total number of aircraft under contract to six. The separate Lot 3 advance procurement contract is valued at $29M. Boeing's H-47 Chinook Block II expands upon 60 years of partnership with the U.S. Army. During that time, Boeing has delivered over 1,000 Chinooks to the U.S. Army, continuously modernizing the helicopter to meet evolving needs," the company stated.

09:26 EDT 22nd Century adds Creager Mercantile as distribution partner for VLN products - 22nd Century Group announced that the Company has added Creager Mercantile as a distribution partner to expand availability and support for its VLN reduced nicotine content cigarette products in the state of Colorado.

09:24 EDT Sunworks taps Zeep Technology for recycling program - Sunworks is advancing its commitment to sustainable practices with the launch of a nationwide, long-term recycling program in contract with asset disposal firm, Zeep Technology. Sunworks' agreement with Zeep emerged after the company recycled 293 decommissioned panels in 2021 and recognized the need to formalize the program. The company's ESG Advisory Committee then prioritized the development of a comprehensive recycling program, which officially started in August.

09:23 EDT Norwegian Cruise Line to eliminate Covid-19 testing starting October 4 - Norwegian Cruise Line announced that it has updated its global health and safety protocols by removing all COVID-19 testing, masking and vaccination requirements effective Oct. 4, 2022. Given the significant, positive progress in the public health environment, the Cruise Line updated its health and safety guidelines, which are now more aligned with other global travel organizations.

09:21 EDT Rubric issued an open letter to Mereo's shareholders - "Rubric Capital Management an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group issued an open letter to Mereo's shareholders. In its letter, Rubric details Mereo's entrenching tactics in a desperate attempt to once more thwart Rubric's effort to call a general meeting of shareholders. Rubric has delivered yet another revised requisition and is increasing the size of its slate of proposed directors to five director nominees, who it believes will provide the Board with the financial, regulatory, and strategic expertise to maximize value for all shareholders. The five highly qualified candidates for Mereo's Board are: Annalisa Jenkins, MBBS, FRCP, Daniel Shames, MD, Marc Yoskowitz, Justin Roberts, and David Rosen," said Rubric.

09:19 EDT American Power Group, Aemetis conduct demonstrations of V6000 solution - American Power Group and Aemetis demonstrated APG's V6000 Low-Carbon Dual Fuel Solution last week in California for multiple truck fleet owners and operators who transport various products for Aemetis and other businesses in the region. In addition, the group presented to several regulatory agencies and policy makers in Sacramento. Based on existing and anticipated fleet interest, APG's 2014 Freightliner CA125 Cascadia day cab equipped with a Cummins ISX 15L diesel engine will be available for demo at Aemetis's Keyes, California renewable fuel production facility for the foreseeable future.

09:17 EDT Gluskin Sheff announces new insurance solution - Gluskin Sheff + Associates announced that Zak Goldman, Jonah Mayles and Brett Okorofsky have joined Gluskin Sheff Financial Services from Sterling Park Financial Group. Gluskin Sheff clients can now directly access customized insurance solutions to address their individual needs through GSFS, a subsidiary of Gluskin Sheff.

09:16 EDT LPL Financial announces Bodnar Financial Advisors joined its platforms - LPL Financial LLC announced that Bodnar Financial Advisors has joined LPL Financial's broker-dealer, RIA and custodial platforms. The team reports serving approximately $300M in advisory, brokerage and retirement assets, and joins LPL from Cambridge Investment Research. Scott Posner, LPL Executive Vice President, Business Development, added, "We welcome Bodnar Financial Advisors to the LPL community and are honored they turned to us to help them build their ideal practice. LPL is a champion in the marketplace for financial advisors and we are centered on empowering advisors so they can do what's best for their clients. We do this by delivering the integrated tools, services and differentiated experiences, all designed to help advisors expand their value proposition and build stronger connections with clients."

09:15 EDT Metals Company appoints Greig to board of directors, Khama to audit committee - The Metals Company announced that Andy Greig has been appointed to its Board of Directors. Greig joined the Board as a director on September 29, 2022 and replaces outgoing director Gina Stryker. Andy brings extensive experience working on international construction projects in the mining sector during a 35-year career at leading engineering, procurement and construction company, Bechtel Group. The Company also announced that the current Chair of its Sustainability & Innovation Committee and Independent Director, Sheila Khama, will join its Audit Committee.

09:14 EDT Raymond James Investment Management completes rebrand - Raymond James Investment Management announced that its new brand identity is now effective. The company, formerly known as Carillon Tower Advisers, initially announced the new brand name in June. The Raymond James Investment Management reinforces the alignment of culture and values with Raymond James, while enhancing overall brand awareness to position the company for future growth and expansion. "The roll-out of the Raymond James Investment Management brand signifies the strength of our commitment to deliver top-quality service to our clients and stakeholders, while providing continued independence for its affiliate firms on a cohesive platform for growth within the multi-boutique asset management space," said Paul Reilly, Chair and CEO of Raymond James.

09:13 EDT Complete Solaria to become pubic through Freedom Acquisition I combination - Complete Solaria (CSLR) and Freedom Acquisition I Corp. (FACT), a publicly traded special purpose acquisition company, announced a definitive agreement for a business combination that will result in Complete Solaria becoming a publicly listed company. Upon the closing of the business combination, the company is expected to remain listed on the New York Stock Exchange under the new ticker symbol (CSLR). Complete Solaria is the result of a merger between Complete Solar and Solaria, which is expected to be completed in the fourth quarter of 2022, subject to customary closing conditions. On a pro forma combined basis, Complete Solaria generated $80M in revenue in 2020, which is projected to increase to over $120M in 2022, and more than double to approximately $285 million in 2023, with the expectation of achieving breakeven EBITDA in the second half of 2023. Will Anderson, CEO of Complete Solar, will become CEO of Complete Solaria. The business combination values Complete Solaria at an implied $553M pro forma enterprise value, at a price of $10.00 per share, prior to any potential redemptions by Freedom's public stockholders. The pro forma enterprise value implies 1.9x the company's projected 2023 revenue. The business combination transaction is expected to provide gross proceeds of $376M, prior to any potential redemptions and payment of transaction expenses, which includes $346M of cash held in Freedom's trust account and promissory notes from certain investors. T.J. Rodgers and sponsor shareholders of Freedom Tidjane Thiam, Edward Zeng and Adam Gishen have entered into a binding agreement to purchase $7M of convertible promissory notes, demonstrating their commitment to the transaction. In addition, potential exists for investments of up to $23M from additional investors prior to the consummation of the proposed business combination of Complete Solaria with Freedom. All Complete Solaria shareholders will roll 100% of their equity holdings into the new combined company. The business combination transactions between Complete Solaria and Freedom have been approved by the boards of each of Complete Solar, Solaria and Freedom. The transaction will require the approval of the stockholders of Freedom and Complete Solaria, and is subject to satisfaction or waiver of the conditions stated in the definitive agreements and other customary closing conditions, including review by the Securities and Exchange Commission. The merger of Complete Solar and Solaria is currently expected to close in the fourth quarter of 2022, and the business combination between Complete Solaria and Freedom is currently expected to close in the first half of 2023.

09:12 EDT South State Chief Banking Officer Greg Lapointe to retire in December, 2023 - SouthState announced that SouthState Chief Banking Officer Greg Lapointe will retire in December 2023. Lapointe will transition to an advisory role April 1, 2023 and retire on December 31, 2023.

09:11 EDT AIkido Pharma purchases 41,096 shares of common stock - AIkido Pharma provided an update on the $3M share repurchase program authorized by the company's Board of Directors on January 21, 2022. The company reported that on September 30, the company purchased 41,096 shares of common stock at $ 7.1034 per share. Anthony Hayes, CEO of Aikido stated, "The company's stock price is still below our book value, so we are continuing to allocate capital under our repurchase plan. The board believes in the company and our plans moving forward."

09:09 EDT EVmo partners with Trek World on three-year, multi-vehicle agreement - EVmo announced the signing of a three-year, multi-vehicle agreement with Trek World USA that will provide vehicles for use in non-emergency healthcare transportation. The agreement will initially be in the state of Illinois and then expand nationwide over the next three years. "Corporate services are an exciting growth area for EVmo," commented Stephen Sanchez, CEO of EVmo. "As we continue to build out our fleet, partnerships like this will help us expand our geographic footprint and strengthen our already high fleet utilization metrics. We are excited to partner with an innovative industry leader like Trek World USA and look forward to growing with them in Illinois and other locations to help them meet the transportation needs of underserved communities."

09:09 EDT Prologis completes acquisition of Duke Realty - Prologis (PLD) announced the completion of its all-stock acquisition of Duke Realty (DRE) following approval by the shareholders of Prologis and Duke Realty. Valued at approximately $23B, including the assumption of debt, the completed transaction expands Prologis' presence in key U.S. markets. Prologis also announced that Duke Realty's Chairman and CEO James Connor has been appointed to the Prologis Board of Directors effective immediately upon the closing of the acquisition.

09:07 EDT Comtech awarded a contract by Tier-1 MNO for over $30M+ - Comtech announced that it has been awarded a contract for over $30M with a multinational data networking and telecommunications equipment company for their text messaging platform. As a pioneer in the SMS industry providing messaging solutions globally since 1996, Comtech has deep experience with its customers' networks, use cases, and messaging features. Comtech's messaging solutions have 99.999% reliability, minimize costs to customers and increase end-user loyalty and satisfaction.

09:06 EDT Hyundai Motor America reports September sales of 59,465 units, up 11% y/y - Hyundai Motor America reported total September sales of 59,465 units, up 11% compared with September 2021. Total and retail sales for Elantra HEV, IONIQ 5, Santa Cruz, Santa Fe HEV, Tucson, Tucson PHEV and Veloster N were the best-ever for September. SUVs were 68% of retail sales, representing a 1.4ppt increase year-over-year. Hyundai did not have fleet sales for the ninth consecutive month, prioritizing inventory for its dealers and consumers.

09:06 EDT Vera Bradley to donate percentage of sales to breast cancer research - Vera Bradley announced that Vera Bradley will donate 100% of primary net proceeds from its second NFT drop; 100% of net proceeds from its limited-edition Hope Charity Pouch; and 20% of the purchase price of its new Rose Toile and Happiness Returns Pink patterns, to the Vera Bradley Foundation for Breast Cancer in support of National Breast Cancer Awareness Month. Vera Bradley's second NFT drop, the 1982 Collection, is now available for purchase through The World of Vera Bradley, the brand's new metaverse concept, or via OpenSea. The 1982 Collection is comprised of 1,982 generative backgrounds derived from 40 archived prints to commemorate the year the company was founded. Priced at $19.82 USD*, the 1982 Collection appeals to crypto lovers and breast cancer awareness supporters alike, with 100% of Vera Bradley's primary net proceeds benefiting the Foundation, focusing its unique utility on advocacy and fundraising. Designed to honor and give hope to those affected by breast cancer, Vera Bradley's limited-edition Hope Charity Pouch features the word "HOPE," surrounded by delicate floral embellishments and boldly emblazoned on a canvas zip-closure pouch. The Hope Charity Pouch, available online at www.verabradley.com and in Vera Bradley Full Line Stores nationwide, is priced at $20, with 100% of net proceeds directed to the Foundation.

09:05 EDT Timber Pharmaceuticals announces $1.3M registered direct offering - Timber Pharmaceuticals announced that it has entered into a securities purchase agreement with several institutional accredited investors to sell in a registered direct offering 13,000,000 shares of the Company's common stock, par value $0.001 per share and Series 1 common warrants to purchase up to an aggregate of 13,000,000 shares of Common Stock at a purchase price of $0.10 per share and associated warrant. The Series 1 Warrants will be immediately exercisable at an exercise price of $0.10 per share and will expire two and one-half years following the initial exercise date. In a concurrent private placement, the Company has also agreed to issue to the investors: Series 2 warrants to purchase up to an aggregate of 13,000,000 shares of Common Stock, and 13,000 shares of Series B Mirroring Preferred Stock. Each share of Series B Preferred Stock will have a stated value of $0.001 per share. The Series 2 Warrants will become exercisable six months following the date of issuance at an exercise price of $0.12 per share and will expire two and one-half years following the initial exercise date. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The Company expects to call a special meeting of stockholders for the approval of a proposal to effect a reverse split of the Common Stock. The Series B Preferred Stock has voting rights on the Proposal equal to 10,000,000 votes per share of Series B Preferred Stock. The voting rights of the Series B Preferred Stock were established in order to maintain the Company's NYSE American listing by raising the average minimum bid price of the Common Stock to over $0.20 for 30 consecutive trading days. The closing of the offerings is expected to occur on or about October 3, 2022, subject to the satisfaction of customary closing conditions. Additional information regarding the securities described above and the terms of the offerings will be included in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission. The Company intends to use the net proceeds from the offerings for working capital and general corporate purposes.

09:04 EDT Rocket Companies CFO Julie Booth to retire, Brian Brown to succeed - Rocket Companies announced the retirements of Julie Booth, CFO and Treasurer effective November 15, 2022, and Angelo Vitale, General Counsel and Secretary effective October 3, 2022. Both Booth and Vitale will remain with the company in strategic advisory roles. Booth joined Rocket Mortgage 19 years ago and has served as the organization's CFO since 2005. She plans to stay in her current role until November 15, 2022, after which she will transition to an advisory role within the company. The board has appointed Brian Brown, Rocket Companies' current Chief Accounting Officer, as the incoming CFO and Treasurer.

09:03 EDT L3Harris Technologies to acquire TDL product line from ViaSat for $1.96B - L3Harris Technologies (LHX) announced the signing of a definitive agreement to acquire Viasat (VSAT) Tactical Data Links, or TDL, product line for approximately $1.96B, subject to customary adjustments. L3Harris will acquire the TDL product line from Viasat's Government Systems Segment, consisting of Link 16 Multifunctional Information Distribution System platforms and associated terminals, which are installed in more than 20,000 U.S. and allied platforms around the world. Viasat's TDL product line is comprised of 450 employees and generates approximately $400M in annual sales. The cash acquisition will be funded with debt financing and includes a net present value of $350M in tax benefits. The deal is expected to close in the first half of 2023, subject to required regulatory approvals and clearances and other customary closing conditions.

09:03 EDT Y-mAbs Therapeutics announces data for omburtamab - Y-mAbs Therapeutics announced clinical data on the Company's product candidate OMBLASTYS for the treatment of CNS/leptomeningeal metastasis from neuroblastoma. Data was presented by Dr. Kim Kramer from Memorial Sloan Kettering, MSK, Cancer Center at the International Society of Pediatric Oncology Annual Congress held September 28 through October 1, 2022, in Barcelona, Spain. In an oral presentation, Dr. Kramer presented interim results for 32 patients enrolled in the Company's ongoing pivotal 101 multicenter study of omburtamab radiolabeled with Iodine-131. The results showed a twelve-month overall survival of 73.5%, with a median follow-up of 25 months. Further, the interim results showed an objective response rate of 31.3% in the patients with measurable disease after central review based on Response Assessment in Neuro-Oncology criteria and European Association of Neuro-Oncology/European Society for Medical Oncology criteria, and that a total of 75.0% of the patient with measurable disease achieved disease control. Serious Adverse Events was found in 40.6% of the patients and were mostly related to myelosuppression. "We are excited to report these data that together with Study 03-133 is the basis of our BLA," said Thomas Gad, President, and Interim Chief Executive Officer. "The disease burden these patient and their families are facing represent a significant unmet medical need, which we hope to be able to address with OMBLASTYS after our PDUFA date on November 30, 2022."

08:55 EDT Trinity Biotech appoints Aris Kekedjian as chairman, CEO - Trinity Biotech announced the appointment of Mr. Aris Kekedjian as CEO with effect from October 3, 2022. He succeeds Mr. Ronan O'Caoimh, co-founder of Trinity Biotech, who will remain on the Trinity Biotech plc Board of Directors to advise the Company going forward. In addition, Mr. Kekedjian has also assumed the role of Chairman of the Board of Directors of Trinity Biotech plc. The company said, "Mr. Kekedjian' s appointment as CEO of Trinity Biotech coincides with what Trinity Biotech believes is a period of fundamental transformation in the diagnostic landscape. The Company expects that increasing utilisation of digital health and virtual care, along with the changes in consumer behaviour brought about by COVID-19, will drive a move to increased decentralised diagnostic testing - an area in which Trinity Biotech has held a leading position for over 20 years. Over the past two years Trinity Biotech has been repositioning itself to capitalise on this change, with a goal of building a world-class executive team driven to scale solutions in this evolving, digitising and interconnected diagnostic ecosystem. Mr. Kekedjian's appointment introduces a proven global business leader to complement a number of recent senior executive hires from leading global companies." Most recently, Mr. Kekedjian served as President & Chief Executive Officer at Icahn Enterprises, Senior Advisor to ECN Capital, and Independent Director of various public companies including Xerox Corporation, Finserv Acquisition Corp. and XPO Logistics, Inc.

08:52 EDT Heico acquires TRAD, terms not disclosed - HEICO Corporation announced that its 3D PLUS subsidiary acquired TRAD SAS for all cash consideration paid at closing. 3D PLUS is part of HEICO's Electronic Technologies Group. Further financial details were not disclosed. HEICO stated that it expects the acquisition to be accretive to its earnings within a year after closing. Labege, France-based TRAD is a leader in the highly specialized field of radiation engineering, which includes test and simulation of radiation effects on electronic components and materials, developing and providing software for radiation testing and effects modeling, and sourcing/screening radiation tolerant and radiation hardened components for its customers. TRAD's services and products are used primarily in the space, nuclear and medical fields. TRAD was founded in 1994 and built up by its CEO, Dr. Christian Chatry, and, soon after, by the Company's now Vice President of Operations, Dr. Nathalie Chatry. The Chatrys added critical capabilities and established TRAD in an important industry place for understanding radiation's and other conditions' impact on electronic components. TRAD employs approximately 75 people at its Labege and Montpellier, France facilities. Nearly two-thirds of TRAD's Team Members are degreed engineers and the Company counts 15 PhD-holders among them. The Chatrys will continue leading TRAD in their same positions post-closing and HEICO stated that it does not expect any staff turnover to result from the acquisition. Further, HEICO commented that TRAD will remain in its existing facilities.

08:49 EDT Engine Gaming's Frankly Media, Aggregated Media enter partnership - Frankly Media announced a partnership with Aggregated Media, an esports and video game culture media company. The partnership enables Frankly to monetize A8's content via their premium yield advertising services and maximize their audience reach through Frankly's video streaming platform, mobile apps and OTT/CTV.

08:47 EDT Sientra launches educational programs for Breast Cancer Awareness Month - Sientra announced the launch of several initiatives in honor of Breast Cancer Awareness Month. as part of their long-standing commitment to breast cancer awareness and education Sientra has partnered with actress and breast cancer survivor, Miranda McKeon; collaborated with the Brem Foundation to launch "Sientra Supports"; and continues to support Reshaping Lives: Full Circle. In addition, Sientra has also partnered with the Brem Foundation, a non-profit organization that seeks to maximize women's chances of finding early, curable breast cancer through education, access, and advocacy, to launch Sientra Supports. This nationwide program will support Brem Foundation's Re-Bra program by providing women who have undergone breast augmentation or breast reconstruction the opportunity to donate gently used pre-surgery bras to low-income women in need. All these programs are in addition to Sientra's large-scale support of Reshaping Lives: Full Circle, a nationwide program aimed at providing free reconstructive breast surgery for post-mastectomy women living in poverty across the U.S.

08:44 EDT Trinity Industries announces $1.8B multi-Year railcar order - Trinity Industries (TRN) announced that its subsidiary, Trinity Rail Group has entered into a new long-term railcar supply agreement with GATX Corporation (GATX) to deliver a mix of 15,000 newly built tank and freight railcars over a six-year period. GATX has the option to order an additional 500 railcars in each order year. Under the terms of the agreement, Trinity will deliver 6,000 tank cars at a rate of 1,200 cars each year from 2024 through 2028. The remaining 9,000 cars, which can be a mix of freight and tank cars, will be ordered at a rate of 1,500 cars per order year from 2023 to 2028 and delivered under a schedule to be determined. "This multi-year railcar order with GATX represents the extension of a strong partnership," said Jean Savage,Trinity's Chief Executive Officer and President. "We are proud of the relationship we have built with GATX and pleased that they have once again selected TrinityRail as the premier North American railcar manufacturer."

08:43 EDT BTCS announces appointment of Pump to board of directors - BTCS announced the appointment of Melanie Pump as a new independent director to its Board. Pump serves as Chief Financial Officer at Polymath Research where she leads their Finance, HR, and compliance efforts.

08:42 EDT Daxor announces new data on BVA-100 blood test - Daxor announces new data validating the benefits of the Company's BVA-100 blood test for heart failure patients. Data were presented at the Heart Failure Society of America Annual Scientific Meeting 2022 - which brought together the world's leading experts in heart failure from September 30th thru October 3rd, 2022, in Washington, DC. Jonathan Feldschuh, Chief Scientific Officer stated, "This study shows the substantial benefit of BVA-guided care for Medicare patients with heart failure. Reducing the mortality rate by 81% on a 30-day basis and 85% on a one-year basis for one of the leading causes of death in the U.S. has been shown to be attainable with BVA in this 216 patient study. The study also showed a 56% lower rate of 30-day rehospitalization which points to a strong economic benefit for payers." The study titled "Heart Failure Outcomes with Volume-guided Management in an Over-65 Population" showed this cohort of patients experienced markedly better outcomes vs. controls for 30-day readmissions, 30-day mortality, and 365-day mortality rates.

08:40 EDT Triumph Bancorp appoints Curtis as EVP, Chief Relationship Management Officer - TriumphPay, a division of TBK Bank, SSB, announced the appointment of Dan Curtis as executive vice president, EVP, chief relationship management officer. In this role, Curtis will provide strategic leadership for TriumphPay's client relationship team, as well as identify key business drivers for clients and ensure TriumphPay is meeting client demands. Prior to joining TriumphPay, Curtis most recently worked as president of BNSF Logistics.

08:39 EDT Adeia completes tranformation to IP licensing company - Adeia announced that it has completed its transformation to become an independent intellectual property licensing company, following completion of the spin-off of its product business. Adeia will continue to trade on the Nasdaq under the new stock symbol "ADEA". Adeia's IP licensing platform provides access to innovations which allow its customers, who are some of the largest media, entertainment, consumer electronics, social media, and semiconductor companies in the world, to create cutting-edge technology solutions and products. Adeia's engineers and inventors are focused on innovating and creating the most advanced, revolutionary, and forward-thinking solutions to help solve challenges facing the media and semiconductor industries. The Company's internal innovation engine accounts for approximately 85% of its combined patent portfolio and generates ideas that are converted into powerful IP, enabling fundamental technologies in its target markets.

08:37 EDT Acer, Relief announces receipt of notice of allowance of US patent covering kit - Acer Therapeutics (ACER) and RELIEF THERAPEUTICS (RLFTF) announced that the US Patent and Trademark Office, USPTO, has issued a Notice of Allowance to Acer for US patent application No. 16/624,834 for claims related to a kit comprising a combination therapeutic product composed of sodium phenylbutyrate or glycerol phenylbutyrate and sodium benzoate. The patent application is exclusively licensed to Acer from Baylor College of Medicine. "This Notice of Allowance expands ACER-001's patent protection and adds an additional component to our product expansion strategy as we evaluate how to maximize its potential," said Jeff Davis, Chief Business Officer at Acer. "The combination of phenylbutyrate and sodium benzoate was synergistic at removing ammonia in healthy subjects based on data from a study published in Genetics in Medicine in 2018.1 As a result, this combination offers the potential to use lower drug doses of each agent while maintaining equivalent ammonia removal in urea cycle disorder patients and becomes part of our lifecycle planning for ACER-001, subject to FDA approval in this indication."

08:37 EDT SilverBow Resources to acquire oil and gas assets in Texas for $87M - SilverBow Resources announced it has entered into a definitive agreement to acquire oil and gas assets in DeWitt and Gonzales counties from an undisclosed seller for a cash purchase price of $87M, subject to customary closing adjustments. The acquisition has an effective date of June 1 and is expected to close in the fourth quarter of 2022. The total purchase price is approximately $87M in cash, subject to customary closing adjustments. SilverBow intends to fund the Acquisition and related fees and expenses with cash on hand and borrowings under its revolving credit facility.

08:36 EDT GATX in long-term railcar pact with Trinity for 15,000 railcars through 2028 - GATX Corporation (GATX) has entered into a new long-term railcar supply agreement with a subsidiary of Trinity Industries to purchase 15,000 newly built railcars through 2028, with an option to order up to an additional 500 railcars each year from 2023 to 2028. The agreement enables GATX to order a broad mix of tank and freight cars. Trinity will deliver 6,000 tank cars at a rate of 1,200 cars each year from 2024 through 2028. The remaining 9,000 cars, which can be a mix of freight and tank cars, will be ordered at a rate of 1,500 cars per order year from 2023 to 2028 and delivered under a schedule to be determined. "This agreement provides GATX with guaranteed access to high-quality, modern and cost-advantaged railcars in North America," said Robert C. Lyons, president and chief executive officer of GATX. "With our existing supply agreements scheduled to expire at the end of 2023, this is an opportune time to establish a new agreement with Trinity, a proven supplier to GATX. We now have long-term access to a wide range of car types, enabling us to continue serving our large and diverse customer base. We expect this order will cover our base fleet reinvestment needs in North America through 2028, and we will continue to pursue additional attractive investment opportunities in the new and secondary railcar markets."

08:35 EDT Interpublic Group announces acquisition of RafterOne - Interpublic announced that it has acquired RafterOne. RafterOne will continue to focus on building around Salesforce to support clients across the IPG network that want to leverage the CRM platform. Terms of the deal were not disclosed. RafterOne works with brands to architect and implement scaled Salesforce solutions that connect brands with customers through end-to-end commerce experiences. IPG CEO Philippe Krakowsky commented, "Our clients are looking for partners that help them adapt strategies and find new ways to interact with customers across physical and digital environments. Salesforce has become a priority platform for marketers to thrive in the digital economy and RafterOne delivers highly personalized content that engages and converts in a measurable, precise and repeatable way. RafterOne has created a team that values collaboration and accountability. In our work with them to date, we've found that our cultures are very complementary, and we are excited to have them bring their specialized Salesforce capabilities for commerce, service, data, marketing, and customer experience to our clients and agencies across the group."

08:34 EDT Canacol Energy says gas sales averaged 166 MMscfpd in August - Canacol Energy is pleased to provide the following information concerning its August and September 2022 natural gas sales and the results of the Canaflecha 2 and Claxon 1 wells, along with the exploration drilling plans for the remainder of 2022. Realized contractual natural gas sales were 166 million standard cubic feet per day for August 2022, and 191 MMscfpd for September 2022. In the month of August consumption of gas by thermoelectric generators on the Atlantic coast decreased due to the maintenance of electrical networks. This, coupled with high reservoir levels due to intense rains, temporarily reduced interruptible gas sales which recovered to normal levels in September. The Corporation completed the drilling of the Claxon 1 exploration well located on the VIM-5 Exploration and Production contract operated by CNE OIL & GAS S.A.S. with 100% working interest. Claxon 1 is located approximately 2 kilometers to the south of the Alboka 1 discovery which tested 33 MMscfpd from the Cienaga de Oro sandstone reservoir. Claxon 1 was spud on July 25, 2022 and reached a total depth of 11,708 feet measured depth on August 15, 2022. The well encountered multiple gas filled sandstones between 7,725 and 8,950 feet true vertical depth within the primary CDO sandstone reservoir target. The well was completed and perforated between 9037 - 9062 and 9101 - 9172 ft TVD. Both Claxon 1 and Alboka 1 are currently being tied into permanent production, after which Claxon 1 will be production tested. The Corporation completed the drilling of the Canaflecha 2 well located on the Esperanza Block, operated by CNE OIL & GAS S.A.S. with 100% working interest. Canaflecha 2 was spud on August 11, 2022 and reached a total depth of 7,394 ft md on August 20, 2022. The well encountered multiple gas filled sandstones between 4,250 and 6,400 ft TVD within the primary CDO sandstone reservoir target. Following completion, the CDO was perforated between 6612 - 6635 and 6654 - 6668 ft TVD. The well was tied into permanent production via an existing 4-inch flow line and tested for 37 hours at an average rate of 4.3 MMscfd and a final rate of 6.5 MMscfpd. Following the test, the well was placed on permanent production. The Corporation completed the drilling of the Clarinete 7 development well located on the VIM-5 E&P contract operated by CNE OIL & GAS S.A.S. with 100% working interest. Clarinete 7 was spud on September 12, 2022 and reached a total depth of 7,479 ft md on September 18, 2022. The well encountered multiple gas filled sandstones between 5,800 and 6,050 ft TVD within the primary CDO sandstone reservoir target. The well has been tied into permanent production The Corporation has contracted a rig and is preparing the location for the drilling of the Saxafon 1 exploration well located on its 100% working interest VIM 5 E&P contract. Saxafon 1 will target gas bearing sands within the CDO and Porquero reservoirs. The Corporation anticipates that the well will spud in November 2022 and will take approximately six weeks to drill, complete, and test. The Corporation is preparing the location for the drilling of the Chimela 1 exploration well located on its 100% working interest VMM 45 E&P contract. Chimela 1 will target gas bearing sandstones within the Tertiary Lisama reservoirs. These sandstone reservoirs are productive in various nearby oil and gas producing fields. The Corporation anticipates that the well will spud in November 2022 following mobilization of the rig from the Clarinete 7 location and will take approximately six weeks to drill, complete, and test. The Corporation is preparing the location for the drilling of the Dividivi 1 exploration well located on its 100% working interest VIM 33 E&P contract. Dividivi 1 will target gas bearing sandstones of the CDO reservoirs. The Corporation anticipates that the well will spud in November 2022 and will take approximately four weeks to drill, complete, and test. The Corporation has contracted a rig and is preparing the location for the drilling of the Natilla 1 exploration well located on its 50% operated working interest SSJN 7 E&P contract. Natilla 1 will target gas bearing sandstones within the CDO and Porquero reservoirs. The Corporation anticipates that the well will spud in November 2022 and will take approximately fifteen weeks to drill, complete, and test. The Corporation has successfully completed the acquisition of 496 square kilometers of 3D seismic located on the VIM-5 E&P contract operated by CNE OIL & GAS S.A.S. with 100% working interest. The 3D seismic survey was acquired in an area previously not covered by 3D seismic and is adjacent to 3D seismic coverage over the Corporation's active producing area. Based on fast track processing and interpretation of an early portion of the survey several CDO and Porquero exploration prospects have been identified for the 2023 drilling campaign.

08:33 EDT Werner signs definitive agreement on acquisition of FAB9 - Werner Enterprises announced it has signed a definitive agreement and closed on the acquisition of FAB9, doing business as Baylor Trucking. "Baylor, with its highly-skilled professional drivers and non-driver associates, further strengthens our portfolio with their exceptional service and stellar reputation," said Derek Leathers, Chairman, President and Chief Executive Officer. "I have known Cari Baylor for many years and I have tremendous respect for what Cari, her family and her leadership team have created at Baylor. This acquisition delivers on our Werner DRIVE strategy and will position us for further growth. We expect this transaction to be accretive in year one and anticipate buying power synergies through integrated management of our combined fleets." Strategic and Financial Benefits: Addition of 234 drivers; Fleet of 200 trucks and 980 trailers; Existing Baylor leadership; Freight revenues mix of one-way dry van, expedited dry van and refrigerated; Buying power synergies are expected through combined management of our two fleets; Both Werner and Baylor have similar cultures that are intensely focused on safety and superior customer service; Baylor will operate as a standalone business unit within Werner.

08:32 EDT COMSovereign Holding receives certification from Mexico's IFT for Fastback radio - COMSovereign Holding announced that following receipt of the required certifications from Mexico's Federal Telecommunications Institute, its Fastback AnyLOSa IBR 1300 is approved sales to all tier one wireless carriers and private wireless network operators in Mexico. The full certification in Mexico follows extensive testing and evaluation by the country's regulatory agency.

08:31 EDT Modular Medical: Submission timeline for MODD1 pump to experience delays - Modular Medical provided an update on its insulin pump product. The company said it has successfully completed the majority of the tests and documentation required for its 510(k) submission with the U.S. FDA of its MODD1 insulin pump product. However, in one of its qualification tests, the company experienced a materials/sterilization process compatibility issue, which has delayed the submission to the FDA, it said. Tests are underway to identify a solution, and, if the product needs to undergo qualification for a new sterilization method, the submission timeline will experience further delays. The company now expects to make its submission to the FDA between December 2022 and June 2023 and intends to provide further updates after the required additional testing has been completed. Modular said: "Progress on developing production manufacturing capability has been promising. The Company is in the process of transferring production to a tier 1 contract manufacturer located in North America as part of its efforts to shorten and onshore its supply chain. Currently, this project is both ahead of schedule and initial cost estimates are in line with or better than the Company's initial internal estimates. Key initiatives on manufacturability, parts list reduction, and materials cost reductions are in process."

08:29 EDT Xometry appoints Matt Leibel as CTO, Brendan Sterne as CPO - Xometry announced the promotion of Matt Leibel to Chief Technology Officer and the appointment of Brendan Sterne as Chief Product Officer. The appointments were announced by Randy Altschuler, CEO of Xometry. Leibel, who joined Xometry in 2019, has played a critical role in the continuing development of Xometry's proprietary AI algorithms, fintech and cloud-based software solutions. Sterne, an expert in scaling products that drive market share and revenue growth, joins Xometry as Chief Product Officer from Indeed.

08:25 EDT DMG Blockchain Solutions goes live on Bosonic Network - DMG Blockchain Solutions announces it has been onboarded and is now actively trading on the Bosonic Network. Using Bosonic's decentralized Financial Market Infrastructure technology, DMG is exchanging its bitcoin to fiat currency at a lower cost with lower risk versus traditional exchanges. In addition, DMG is working with Bosonic to offer its dFMI technology to all Terra Pool members. In September 2022, DMG mined 77 bitcoin with 0.65 EH/s realized hashrate. For the September quarter, DMG mined 200 bitcoin. DMG's bitcoin balance as of September 30, 2022 was 344 bitcoin. DMG is on-target with respect to its original schedule for received miner deliveries for growing its hashrate to 1 EH/s by the end of calendar 2022, subject to the receipt, installation and operation of the additional miners.

08:24 EDT APA Corp. sees Q3 U.S. production above high end of August guidance - U.S. production is expected to be above the high end of the third-quarter guidance range provided in August, 212 Mboe/d. International volumes are expected to be below the low end of the third-quarter guidance range, 171 Mboe/d. With respect to international volumes, the shortfall is related to North Sea production, which was approximately eight Mboe/d below guidance due to significant unplanned downtime in August and September.

08:22 EDT Novo Nordisk reports ONWARDS 5 trial achieved primary endpoint - Novo Nordisk announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin in 1,085 insulin-naive people with type 2 diabetes in a clinical practice setting including fewer trial visits compared to the other ONWARDS phase 3a trials. Once-weekly insulin icodec was used in combination with a dosing guide app to guide titration. The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 52 with insulin icodec compared with once-daily basal insulin analogues. From an overall baseline HbA1c of 8.9%, once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of -1.68%-points compared with -1.31%-points for the once-daily basal insulins. In the trial, there was no statistically significant difference in estimated rates of severe or clinically significant hypoglycaemia with 0.19 events per patient-year exposed to once-weekly insulin icodec and 0.14 events per patient-year exposed to the once-daily basal insulins. In the trial, once-weekly insulin icodec appeared to have a safe and well-tolerated profile.

08:21 EDT Blue Apron plunges 23% after stock sale announcement, Q3 revenue outlook

08:21 EDT Clene reports results from Healey ALS Platform trial of CNM-Au8 - Clene and its subsidiary Clene Nanomedicine announced topline study results showing a survival benefit in the Healey ALS Platform trial of CNM-Au8 in participants with amyotrophic lateral sclerosis. The primary endpoint of slope of change in ALS Functional Rating Scale Revised scores adjusted for mortality was not significant at 24 weeks. Secondary endpoints of Combined Assessment of Function and Survival and slow vital capacity were also not met at 24 weeks across the combined 30 mg and 60 mg CNM-Au8 doses. The prespecified exploratory analyses of the secondary survival endpoint demonstrated a greater than 90% reduction in risk of death alone or in risk of death/permanently assisted ventilation at 24 weeks, when adjusted for baseline imbalances in risk with the CNM-Au8 30 mg dose. These survival results were statistically consistent for the 30 mg dose between the regimen only and full analysis setsl. This survival signal is consistent with results previously reported by Clene in the Phase 2 RESCUE-ALS trial with CNM-Au8. The full analyses, including data on biomarkers of neurodegeneration and exploratory efficacy results, are expected later in 2022. Based on these topline findings, Clene has selected the CNM-Au8 30 mg dose for continued development in ALS. The CNM-Au8 60 mg dose did not demonstrate a survival benefit. CNM-Au8 was well-tolerated, and there were no drug-related serious adverse events or significant safety findings reported.

08:20 EDT Blue Apron: FY22 revenue outlook depends on completion of bulk sales - In a regulatory filing, Blue Apron said: "Our ability to achieve our net revenue growth target for fiscal year 2022 of a 7% to 13% increase in net revenue over net revenue in fiscal year 2021 as we announced on August 8, 2022, depends in part upon the completion of additional bulk sales in one or more transactions to the enterprise customer referred to above in the aggregate amount of approximately $30 million in the fourth quarter of 2022, which amount includes the previously anticipated bulk sales to the enterprise customer in the third quarter. While we are engaged in discussions with the enterprise customer, we have not yet entered into an agreement for such additional bulk sales, and we believe that a significant portion of these bulk sales will be dependent on the enterprise customer's receipt of additional directed donations similar to the June transaction. We cannot provide any assurance as to if or when we will enter into any bulk sales agreements with the enterprise customer in the fourth quarter or in what amounts, or any assurance regarding the timing and amount of any bulk sales to the enterprise customer under any purchase agreement we may enter into with the enterprise customer."

08:18 EDT Blue Apron announces equity distribution agreement with Canaccord Genuity - In a regulatory filing, Blue Apron said it entered into an Equity Distribution Agreement with Canaccord Genuity LLC, as sales agent, pursuant to which the company may issue and sell shares of its Class A common stock, $0.0001 par value per share, having an aggregate offering price of up to $14,999,425, from time to time through the Sales Agent.

08:17 EDT Reed's receives positive Nasdaq listing determination - Reed's announced that, by decision dated September 28, 2022, a Nasdaq Hearings Panel granted Reed's request for an extension until February 13, 2023 to continue the listing of Reed's common stock on The Nasdaq Capital Market. The extension is subject to the Company's timely satisfaction of certain interim milestones and, ultimately, the Company's compliance with all applicable criteria for continued listing on Nasdaq, including the $1.00 bid price and minimum $2.5 million stockholders' equity requirements. "We are pleased that the Nasdaq Hearings Panel has provided us with this extension," said Norman Snyder, CEO of Reed's. "We presented the panel our operating plan that includes several business initiatives which are on track and should contribute to regaining our compliance with Nasdaq, including the continued growth of our flagship Reed's Ginger Beer and Virgil's portfolios, ramping of our RTD alcohol portfolio, various product launches and further expansion of our swing-lid portfolio. Coupled with our various supply chain, transportation and cost saving programs, we believe the value generated by these initiatives will be realized in the broader market and should support our goal of regaining compliance with Nasdaq listing requirements."

08:15 EDT Aqua Metals closes $6M secured loan from Alpen Mortgage - Aqua Metals announced that the Company has closed a $6 million secured loan with Alpen Mortgage, Northern Nevada's Premier Private Lender. The loan provides a non-dilutive path to expand the Company's cash position and ensure sufficient resources to reach revenue generation. The $6 million note was closed on September 30, 2022 and has a 24-month term. The note includes interest at a fixed rate of 8.5%. Monthly payments are interest-only commencing on November 1, 2022. All unpaid principal and remaining accrued unpaid interest is due 24 months from the close date. The loan is secured by commercial property. Additional details regarding the loan will be included on a Form 8-K, to be filed with the Securities and Exchange Commission after closing.

08:14 EDT Biogen, Denali announce initiation of Phase 3 LIGHTHOUSE study - Biogen (BIIB) and Denali Therapeutics (DNLI) announced that dosing has commenced in the global Phase 3 LIGHTHOUSE study to evaluate the efficacy and safety profile of BIIB122, DNL151, as compared to placebo in approximately 400 participants with Parkinson's disease and a confirmed pathogenic mutation in the leucine-rich repeat kinase 2 gene. The primary endpoint of the LIGHTHOUSE study is time to confirmed worsening, as assessed using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) over the treatment period, up to 180 weeks. Participants will be randomized to receive oral BIIB122 or placebo once daily. "In collaboration with Biogen, we are excited to be pursuing the potential of LRRK2 inhibition as an effective treatment for Parkinson's disease," said Carole Ho, M.D., Chief Medical Officer of Denali. "The initiation of the Phase 3 LIGHTHOUSE study marks an important milestone in the BIIB122 development program. Together with the recent initiation of the Phase 2b LUMA study in early-stage Parkinson's disease, we hope to have the opportunity to bring a novel therapeutic option to people living with Parkinson's disease."

08:12 EDT Codexis appoints Rahul Singhvi to board of directors - Codexis announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. He currently serves as the CEO of National Resilience.

08:11 EDT Alignment Healthcare announce new plan options for 2023 Medicare advantage plan - Alignment Health announced new Alignment Health Plan options that offer more value, access and flexibility to 8.3M Medicare-eligible adults this Medicare enrollment season. New offerings include expanded $0-premium Preferred Provider Organization plans, special needs plans for adults eligible for both Medicare and Medicaid, and new benefits to support today's senior lifestyles. Medicare-eligible adults can select from Alignment's diverse portfolio of plans during the annual enrollment period, which runs Oct. 15 through Dec. 7 for plan benefits starting Jan. 1, 2023. "Every year, we grow our range of customized plans, benefits and support for seniors who need and deserve more choice in their care. This mission is increasingly critical as an estimated 10,000 U.S. adults turn 65 every day," said John Kao, founder and CEO of Alignment Health. "Our model puts our members at the heart of everything we do: our plans deliver a breadth of choice and value; our care teams proactively engage members to ensure the best care experience; and our proprietary technology empowers us to deliver customized, coordinated care that drives better health outcomes. As we grow, we continue to show that it is possible to deliver high-quality care at a lower cost and to do it at scale. Our 2023 plan offerings and benefits are designed to empower seniors nationwide to age well, where and how they choose."

08:09 EDT IGI Group appoints Chris Jarvis as Chief Underwriting Officer - International General Insurance Holdings announced that it has appointed the role of Chief Underwriting Officer of the IGI Group, effective today. Jarvis will work with IGI's underwriting team leaders to optimise performance within their existing portfolios in order to support the Group in delivering on its growth and profitability targets. He will also be responsible for evaluating new business opportunities.

08:08 EDT WillScot Mobile Mini completes divestiture of Tank, Pump Business - WillScot Mobile Mini announced it has completed the previously announced divestiture of its Tank and Pump segment to private equity firm Kinderhook Industries effective September 30, 2022. Proceeds from the sale, valued at approximately $323M, will be used to support ongoing reinvestment in the Company's core Modular and Storage operating segments and other capital allocation priorities.

08:07 EDT Enviva Partners reports minimal impact from Hurricane Ian - Enviva reported that Hurricane Ian has resulted in minimal impact to operations and provided details on third quarter and fourth quarter of 2022 expectations, along with an update of certain 2022 financial guidance metrics. The company said, "Enviva prepared in advance of Hurricane Ian to keep employees safe and minimize disruption, most notably at Enviva's storage and terminaling operations located at the ports of Savannah, Georgia, Wilmington, North Carolina, and Chesapeake, Virginia. As a precaution, the Georgia Ports Authority and the North Carolina State Ports Authority ordered the temporary closure of the Port of Savannah and Port of Wilmington, respectively, which suspended operations at our deep-water marine terminals there. The ports have re-opened and Enviva has resumed normal operations. No production facilities were adversely affected by the storm."

08:07 EDT ATIF Holdings announces $2M JV to form ATIF Southern US - ATIF Holdings is pleased to announce that the company has signed Business Partnership Agreement with David Shan on September 26, 2022 to jointly fund a total of $2M to establish ATIF Southern US LLC in Texas to cover the entire southern region of U.S. with ATIF's premium IPO advisory service. Pursuant to the Agreement, the two parties jointly contributed a total of $2M, with 60% of the shares held by ATIF and 40% by David Shan. ATIF Southern will serve as a business branch of ATIF, based in Texas, and extend the company's best-in-class IPO advisory services to outstanding local companies throughout the southern United States. Both parities will jointly select qualified companies for IPOs and the joint capitalization of $2M for operating and investment capital will provide financial support for a successful IPO in major capital markets of U.S.

08:05 EDT BioLife Solutions COO Roderick de Greef to retire - BioLife Solutions announced changes to its Board of Directors and executive management team, all to be effective as of January 3. Roderick de Greef, BioLife President and COO, will retire from management and will re-join the Board of Directors, increasing the number of Directors to seven. de Greef has served BioLife for 22 years as a board member then and as an executive officer since 2016. de Greef served as CFO from 2016 to 2021 and postponed his previously announced retirement of December 2021 to assume the role of COO, with a focus on completing key operational improvement initiatives related to the company's acquisition of Global Cooling. de Greef commented further, "It is with full confidence now that I re-announce my retirement and our plan to hand my global operations responsibilities to Geraint Phillips, current Vice President of Freezer Operations in January 2023. Having worked closely with Geraint over the last year, I have complete faith in his ability to assume a broader role within BioLife by utilizing his decades long operations management experience."

08:04 EDT Ascendis announces recommended Phase 2 dose for transcendIT-101 - Ascendis Pharma announced completion of the dose-escalation portion and recommendation of the Phase 2 dose in transcendIT-101, a Phase 1/2 clinical trial to evaluate the safety and efficacy of TransCon TLR7/8 Agonist in locally advanced or metastatic solid tumors, alone or in combination with pembrolizumab. TransCon TLR7/8 Agonist is a novel investigational product candidate designed for sustained, localized release of resiquimod with low systemic exposure. The abstract for the dose-escalation topline data was accepted for an oral presentation at SITC 2022, the annual meeting of the Society for Immunotherapy of Cancer being held November 8-12 in Boston. All patients in the dose escalation portion of the trial had advanced or metastatic solid-tumors and had progressed on prior treatments. In the next phase of the trial, the recommended Phase 2 dose of TransCon TLR7/8 Agonist will be evaluated in four cohorts focused on cancers where increased Toll-like receptor activity has potential to improve adaptive immune activation and host defense against cancers. The cohorts include head and neck squamous-cell carcinoma other HPV-associated cancers; melanoma; and cutaneous squamous cell carcinoma. In this portion of the study, all participants will be treated every three weeks with intratumoral TransCon TLR7/8 Agonist in combination with intravenous pembrolizumab. Limits on prior lines of therapy vary by cohort. Later this year, Ascendis will initiate a clinical investigation of TransCon TLR7/8 Agonist intratumoral treatment in combination with TransCon IL-2 beta/gamma, the company's product candidate designed for systemic activation of tumor-antigen specific cytotoxic cells.

08:03 EDT Yum! Brands' KFC testing Kentucky Fried Chicken Wraps in Atlanta - Kentucky Fried Chicken is shaking up its menus with the release of its new Kentucky Fried Chicken Wraps in select Atlanta restaurants for a limited time, starting October 3. Kentucky Fried Chicken Wraps are packed with flavor and available in three mouthwatering options for fans to choose from, starting at only $3 each or in a two-wrap combo.

08:02 EDT Codexis appoints Singhvi to board of directors - Codexis announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise. He currently serves as the Chief Executive Officer of National Resilience.

07:43 EDT EbixCash signs strategic partnership agreement with Al Fardan Exchange - EbixCash announced that its Foreign Exchange Division - EbixCash World Money, has signed a strategic partnership agreement with Al Fardan Exchange LLC, UAE for import and export of Foreign Currency Banknotes.

07:38 EDT Chemours announces $200M investment to expand capacity - Chemours, Thermal & Specialized Solutions and Advanced Performance Materials announced a planned $200M investment to increase capacity and advance technology for its Nafion ion exchange materials to support the Hydrogen Economy. Chemours' investment will support growing market demand for clean hydrogen generation using water electrolyzers, energy storage in flow batteries, and hydrogen conversion to power fuel cell vehicles of the future.

07:36 EDT Interfor to acquire Chaleur Forest Products for C$325M - INTERFOR CORPORATION announced that it has reached an agreement with an affiliate of the Kilmer Group to acquire 100% of the equity interests in the entities comprising Chaleur Forest Products. Chaleur owns two modern and well-capitalized sawmill operations located in Belledune and Bathurst, New Brunswick, with a combined annual lumber production capacity of 350 million board feet. Chaleur also operates a woodlands management division based out of Miramichi that manages approximately 30% of the total Crown forest in New Brunswick. This division provides a secure source of fibre supply for the sawmill operations as well as a stable, long-term stream of cash flow from third-party log sales, licence management fees and silviculture activities.The purchase price is C$325M, on a cash and debt free basis, which includes approximately C$31M of net working capital. In addition, Interfor will assume Chaleur's countervailing and anti-dumping duty deposits at closing, for consideration equal to 55% of the total deposits on an after-tax basis. As of August 31, 2022, Chaleur had paid cumulative CV and AD duties of approximately US$82M. On a proforma basis, Interfor's total annual lumber production capacity will increase to 5.1 billion board feet, of which 44% will be in the US South, 19% in Eastern Canada, 15% in the US Northwest, 15% in British Columbia and 7% in Atlantic Canada. The acquisition will be immediately accretive to Interfor's earnings and is expected to provide attractive returns in both the near-term and over the long-term. Interfor estimates Chaleur's mid-cycle EBITDA to be approximately C$50M per year pre-synergies, taking into account mid-cycle lumber prices and current run-rate performance. Interfor expects to achieve synergies of C$5M per year from combined sales and marketing opportunities, shared purchasing programs and general and administrative expense reductions. These synergies are expected to be fully achieved within twelve months of closing, with no capital requirements. Interfor intends to finance the acquisition with a combination of cash on hand and its existing credit facilities. Following the completion of this acquisition Interfor will continue to have significant financial flexibility to execute its strategic capital investment plans and consider additional value-creating capital deployment options. As of August 31, 2022 Interfor had net debt of approximately C$48M and a Net Debt to Invested Capital ratio of 2%. Proforma the Chaleur acquisition and proforma Interfor's C$100M Substantial Issuer Bid completed on September 12, 2022, Interfor's Net Debt to Invested Capital ratio as of August 31, 2022 would remain below 20%. Similarly, proforma liquidity as of August 31, 2022 would be approximately C$322M, before consideration of significant additional borrowing capacity available under existing credit limits and continued near-term operating cash flows. The completion of the acquisition is subject to Canadian and U.S. regulatory reviews and customary conditions for a transaction of this kind and is expected to close in the fourth quarter of 2022.

07:35 EDT Alexion, AstraZeneca Rare Disease to acquire LogicBio for $2.07 per share - Alexion (ALXN), AstraZeneca Rare Disease, announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio Therapeutics (LOGC). The proposed acquisition aims to rapidly accelerate Alexion's growth in genomic medicines through LogicBio's unique technology, experienced rare disease R&D team, and expertise in pre-clinical development. LogicBio has developed technology platforms for the delivery and insertion of genes to address genetic diseases, as well as a platform designed to improve viral vector manufacturing processes. These platforms, coupled with LogicBio's team and Alexion's advancements with AstraZeneca (AZN), will drive future scientific possibilities and next generation medicines to treat rare genetic diseases. Under the terms of the agreement, Alexion, through a subsidiary, will initiate a cash tender offer to acquire all outstanding shares of LogicBio for $2.07 per share. Both boards have unanimously approved the transaction. Alexion plans to close the deal in four to six weeks, subject to the tender of at least a majority of the outstanding shares of LogicBio common stock and satisfaction of other closing conditions, and plans to retain LogicBio employees at their current location.

07:32 EDT Beyond Air announces review of company's third pilot study of inhaled NO - Beyond Air announced that the Annals of the American Thoracic Society published a detailed review of the Company's third pilot study of inhaled nitric oxide, NO, in bronchiolitis patients. The publication offers an overview of the study design and previously announced results, as well as the rationale for conducting a pivotal study. "We're pleased to have published the positive clinical results from our third pilot study of the inhaled NO to treat bronchiolitis in infants in the Annals of the ATS. The results of this study show that high dose inhaled NO given intermittently may be useful in treating patients with moderate to severe bronchiolitis, and supports the need to conduct a larger, confirmatory efficacy study. As previously announced, due to the lingering effects of the pandemic, our bronchiolitis program is on hold and we plan on initiating a study of high concentration inhaled NO to treat viral community-acquired pneumonia using our LungFit Pro system in the fourth quarter of 2023, pending discussions with the FDA," commented Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. On an ITT basis, a significant reduction was observed in the primary endpoint when 150 ppm inhaled NO was compared to 85 ppm inhaled NO and SST alone. No significant difference was observed between 85 ppm NO and the control. For the key secondary endpoint of hospital length of stay, on an ITT basis, the results show statistical significance of the 150 ppm NO arm compared to the other two arms. There was no statistical difference between the 85 ppm NO arm and SST. Also, NO therapy was generally well tolerated. There were no serious adverse events related to NO therapy, with no adverse events leading to discontinuation of NO therapy.

07:30 EDT Estrella Biopharma to go public via merger with TradeUp Acquisition - Estrella Biopharma, a preclinical-stage biopharmaceutical company focusing on cancer therapeutics, and TradeUP Acquisition Corp. announced that they have entered into a definitive business combination agreement on September 30 that will result in Estrella becoming a publicly listed company. Upon closing of the transaction, TradeUP will be renamed "Estrella Immunopharma." The pro forma equity valuation of the Combined Company is expected to be approximately $398.5M. Estimated cash proceeds to the Combined Company from the transaction are expected to consist of TradeUP's approximately $45.4M of cash in trust. Upon the closing of the transaction, and assuming none of TradeUP's public stockholders elect to redeem their shares of common stock and no additional shares of common stock are issued upon the closing of the transaction, it is anticipated that TradeUP's public stockholders would retain an ownership interest of approximately 11.1% in the Combined Company, the sponsors, officers, directors and other holders of TradeUP founder shares will retain an ownership interest of approximately 3.6% of the Combined Company, and the Estrella stockholders will own approximately 81.6% of the Combined Company. The board of directors of each of TradeUP and Estrella as well as stockholders of Estrella approved the transaction, which is expected to close in the first half of 2023. The transaction will require the approval of the stockholders of TradeUP and is subject to other customary closing conditions including the receipt of certain regulatory approvals.

07:27 EDT Algonquin Power to sell portfolio of operating wind projects to InfraRed Capital - Algonquin Power announced it has entered into an agreement to sell ownership interests in a portfolio of operating wind projects in the United States and Canada to InfraRed Capital Partners, an international infrastructure investment manager that is part of SLC Management, the institutional alternatives and traditional asset management business of Sun Life Financial. This inaugural asset recycling transaction consists of the sale of a 49% ownership interest in three operating wind facilities in the United States totaling 551 MW of installed capacity and an 80% ownership interest in a 175 MW operating wind facility in Canada. The U.S. Facilities consist of the Odell Wind Facility in Minnesota, the Deerfield Wind Facility in Michigan and the Sugar Creek Wind Facility in Illinois. The Canadian facility is the Blue Hill Wind Facility in Saskatchewan. AQN will continue to oversee day-to-day operations and provide management services to the facilities. Total cash proceeds to AQN from this asset recycling transaction are expected to be approximately $277M for the U.S. Facilities and approximately C$107M for the Blue Hill Wind Facility, subject to customary closing adjustments. Through its ability to develop, manage construction and perform asset management services, upon closing AQN will have added incremental shareholder value from these four wind projects. This first asset recycling transaction highlights the value-creation potential of AQN's greenfield pipeline of 3,800 MW of solar and wind projects and 1,700 MWh of storage projects announced at its December 2021 Investor Day. Asset recycling, leveraging the scale of AQN's existing renewable energy portfolio, is a key component of the previously announced $12.4B capital plan from 2022 through the end of 2026. Closing of the transaction is subject to receipt of certain regulatory approvals and other customary closing conditions. The transaction is expected to close in the fourth quarter of 2022. As a result of this transaction, and projected close by the end of 2022, the company does not intend to issue any equity through the remainder of 2022 and has ceased issuances under its at-the-market- equity program. Further, with the successful signing of this inaugural asset recycling transaction, the company plans to evaluate further asset sales as a core part of its capital plan for 2023 and beyond.

07:21 EDT Vertiv Holdings CEO Rob Johnson to retire, Giordano Albertazzi to succeed - Vertiv announced that Rob Johnson, CEO, will retire from his position as CEO for health reasons effective December 31. Effective immediately, Giordano Albertazzi, currently president, Americas, has been appointed into the additional role of COO. Further, Albertazzi will succeed Johnson as CEO and as a director on the board of directors on January 1, 2023.

07:19 EDT Goodbody Health announces distribution agreement with Tasso - Goodbody Health announces that that it has signed a contract with Tasso. Tasso produces a signature line of virtually painless medical devices to draw a capillary blood sample with no needles and without the need for a phlebotomist, which can then be shipped to an accredited laboratory for analysis using a compatible sample collection reservoir. This will allow more Goodbody Health clinics and wellness locations as well as other healthcare professionals to undertake the tests requiring more blood than is delivered through the finger prick method. Goodbody expects to be rolling the devices out through its growing network of pharmacies in the UK later this year.

07:17 EDT Nutriband announces application for dual listing on Upstream - Nutriband announced that it has begun the application process to dual list its shares on Upstream. The planned dual listing on Upstream is designed to provide Nutriband the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in NASDAQ-listed Nutriband.

07:16 EDT Red White & Bloom announces exclusive agreement for Skybar vape tech - Red White & Bloom Brands announces an exclusive agreement to utilize vape technology provided by Skybar, a leading innovator in vape devices. In addition, the company is pleased to announce the debut of Platinum Vape Disposables. Platinum Vape and Skybar have extensively collaborated in creating a unique device with a custom tank and flavorful exotic terpenes catered specifically for vape consumers. The product has auto-draw technology with a High-Grade Coil and powerful battery, delivering a smooth and consistent experience without charging or setting adjustments. RWB has seen tremendous success on the launch and is proud to announce that PV Disposables are currently available in 250 dispensaries across Michigan.

07:14 EDT Regenxbio announces 'positive' interim data from trials of RGX-314 - Regenxbio announced a program update from its ongoing clinical investigation of RGX-314 for the treatment of wet AMD, a leading cause of vision loss globally. Regenxbio announced positive interim data from the Phase II AAVIATE trial of RGX-314 for the treatment of wet AMD using suprachoroidal delivery. REGENXBIO also presented positive interim data from the Phase I/IIa long-term follow-up study of RGX-314 for the treatment of wet AMD using subretinal delivery at the American Academy of Ophthalmology annual meeting this past weekend in Chicago. RGX-314 continues to be well tolerated in 85 patients from Cohorts 1-5 with no drug-related serious adverse events; Meaningful reduction in treatment burden at six months across all dose levels, 85% reduction in treatment burden observed at third dose level; 67% of patients in Cohort 4 were injection-free; No meaningful differences in outcomes at six months for patients who are NAb positive; Phase II trial expanded to include new cohort at third dose level with short-course prophylactic ocular steroids following RGX-314 administration.

07:13 EDT Targa Resources releases sustainability report - Targa Resources announced that its Sustainability Report for 2021 is now available on the Company's website. The report advances Targa's sustainability disclosures and provides a review of Targa's performance for calendar year 2021 against various environmental, social, and governance topics that are important to our industry. Highlights of Targa's Sustainability Report for the 2021 calendar year include the following: Reduced scope 1 plus scope 2 GHG intensity by 12%; Reduced flaring volumes from emissions events by 40%; Exported approximately 4.9 billion gallons of liquefied petroleum gas globally in 2021 that can offset higher GHG-emitting fuels; Completed aerial methane detection on 13,000 miles of pipelines and 162 surface facilities in the Permian; Decreased its preventable vehicle accident rate by 31%; Received the International Liquid Terminals Association safety excellence award for the second year in a row; 25% of our Board of Directors were women; and 17% of our Board of Directors were from traditionally under-represented racial or ethnic groups; Our Board-level Sustainability Committee continues to oversee management's implementation of strategy to integrate sustainability into various business activities to create long-term stakeholder value. The report references the Global Reporting Initiative Standards and Sustainability Accounting Standards Board Oil & Gas - Midstream Standard.

07:11 EDT Bitfarms mines 481 new bitcoin in September - Bitfarms provided a Bitcoin production and mining operations update for September 2022. "Reaching 4.2 exahash/second, we achieved our September 30, 2022 target operating hashrate," said Ben Gagnon, Chief Mining Officer of Bitfarms. "During September, we mined 481 BTC, averaging 16 BTC mined per day and exited the month at 17 BTC mined per day. Our increased capacity continues to deliver growth, even while network difficulty increased as much as 13%. A higher network hashrate, due in part to previously idle miners coming back online, and the shorter 30-day month were the primary drivers of lower monthly production compared to August. In the first nine months of 2022, we mined 3,733 BTC, surpassing 2021 full-year production of 3,452 BTC by 8% heading into Q4. With 229 MW planned to be developed by the end of the year, we are well positioned to further grow production in 2023." Mining production in September 2022: 4.2 EH/s online as of September 30, 2022; 3.95 EH/s average online for month of September; 481 new BTC mined; 16.0 BTC mined daily on average.

07:11 EDT Cellebrite appoints Ayala Berler Shapira as general counsel - Cellebrite (CLBT) announced that Ayala Berler Shapira has been named General Counsel of the company. As part of the company's further growth Ayala Berler Shapira will strategically manage all legal aspects and will assume complete responsibility and lead the legal and compliance organization of Cellebrite. She will be a member of Cellebrite's executive management team. Prior to joining Cellebrite, Ayala served as Deputy GC of Amdocs (DOX), where she led the global business and corporate legal domains, supported the company's M&A activity, and served as Head of Compliance.

07:09 EDT Century Therapeutics appoints Daphne Quimi, Timothy Walbert to board - Century Therapeutics (ISPC) announced the appointment of Daphne Quimi and Timothy Walbert to the Company's Board of Directors. Ms. Quimi is CFO of Amicus Therapeutics (FOLD) and brings experience in public accounting and financial reporting to Century. Mr. Walbert is currently Chairman, President, and CEO of Horizon Therapeutics (HZNP), and brings expertise in product portfolio building and commercialization. In conjunction with these new appointments, Century also announced that Eli Casdin, CIO of Casdin Capital, has resigned from the Board of Directors, effective as of October 1, 2022.

07:07 EDT Aura Biosciences announces interim belzupacap sarotalocan study results - Aura Biosciences announced that interim Phase 2 data evaluating the safety and efficacy of suprachoroidal, or SC, administration using its first VDC product candidate, belzupacap sarotalocan, for the first-line treatment of patients with early-stage choroidal melanoma (indeterminate lesions and small choroidal melanoma, were presented at the American Academy of Ophthalmology, or AAO, 2022 Annual Meeting held September 30-October 3, 2022, in Chicago, Illinois. This Phase 2 trial is assessing the safety and preliminary efficacy of single- and multiple ascending-doses of belzupacap sarotalocan up to three cycles of treatment via SC administration for the first-line treatment of early-stage choroidal melanoma. A total of 20 adult patients have been enrolled in the trial including the single dose Cohorts 1-3 and multiple dose escalation Cohorts 4-6 . Cohorts 5 and 6 received up to three cycles of therapy, which was considered the therapeutic regimen for evaluation. One patient in Cohort 5 received two cycles of therapy and two patients in Cohort 5 received three cycles of therapy. All patients from Cohort 6 received three cycles of therapy at the highest dose. One patient from Cohort 6, who discontinued after one cycle due to unrelated serious adverse events, or SAEs, is not included. All patients in Cohorts 5 and 6 had active growth at study entry, as an enrichment strategy to evaluate preliminary efficacy. This group of patients with active growth treated at the therapeutic regimen of three cycles was evaluated for tumor growth rate, tumor control, and visual acuity preservation as the defined clinical endpoints to evaluate preliminary efficacy. These endpoints have been discussed with the U.S. Food and Drug Administration and are planned to be used in the pivotal program. The results, with an average of six months follow up in patients that received three cycles of therapy in Cohorts 5 and 6, showed a statistically significant reduction in the tumor growth rate compared to each patient's documented growth rate at study entry, and an 88.9% tumor control rate. In addition, the visual acuity preservation rate was 88.9% in these cohorts, with the majority of patients being at high-risk for vision loss with tumors close to fovea or optic disk. The overall safety profile of belzupacap sarotalocan was generally favorable, with no dose-limiting toxicities or treatment-related SAEs reported as of August 19. There was no posterior inflammation and only mild anterior inflammation in 20% of the patients. Treatment-related AEs were predominantly mild and resolved without sequalae. We believe these interim results indicate that belzupacap sarotalocan may offer a targeted vision preserving therapy for the first-line treatment of primary CM, where 80% of patients are diagnosed early and have no approved therapies to date.

07:06 EDT Arvinas appoints Paul McInulty as SVP, regulatory affairs - Arvinas (ARVN) announced that Paul McInulty has joined the company as Senior Vice President, Regulatory Affairs. He recently served as Vice President, Therapeutic Head, Hematology and Precision Medicines Regulatory Affairs at Bristol Myers Squibb (BMY).

07:05 EDT RedHill Biopharma: Opaganib, RHB-107, inhibit Omicron sub-variant BA.5 - RedHill Biopharma announced study results showing in vitro efficacy against the currently dominant Omicron COVID-19 sub-variant BA.5, by both of RedHill's novel, oral, host-directed and broad-acting investigational antivirals, once-daily RHB-107 and twice-daily opaganib. These results build on previously reported data on the inhibition of COVID-19, variants of concern and other viruses, and further support their broad-acting, host-directed mechanisms of action. The study was done in collaboration with renowned virologist, Dr. Colleen B. Jonsson, Harriet Van Vleet Professor of Virology, Director of the Regional Biocontainment Laboratory, and Director of the Institute for the Study of Host-Pathogen Systems at the University of Tennessee Health Sciences Center, who remarked: "We tested RHB-107 and opaganib using a primary human nasal epithelial cell culture model of Omicron BA.5, which was specifically selected due to the high level of SARS-CoV-2 entry factor expression in these cells. The results of our work show that both RHB-107 and opaganib inhibit Omicron sub-variant BA.5 viral replication, which is indicative of antiviral activity. Of further interest is the hypothesis that, compared to Delta, Omicron replication is increased as compared to primary epithelial lung cell cultures - hinting at a different possible mechanism of cell entry via membrane fusion and the endocytic pathway. Although we may be potentially dealing with different methods of viral cell entry, these new data suggest that it does not prevent either RHB-107 or opaganib from exerting their viral inhibition capabilities."

07:03 EDT Rockwell Automation to acquire Cubic, terms undisclosed - Rockwell Automation announced that it has signed a definitive agreement to acquire Cubic, a company that specializes in modular systems for the construction of electrical panels. Cubic, founded in 1973, is headquartered in Bronderslev, Denmark. Cubic's established partner model will allow Rockwell to build an expanded Partner Network for intelligent motor control offerings in Asia, Europe, and Latin America. The company will bring new customers and partners in hybrid and process industries. Additionally, Cubic will broaden Rockwell's market access in renewable energy and data center solutions. At close, Cubic will report to Rockwell's Power Control Business in the Intelligent Devices operating segment. Cubic is expected to report more than $75M in sales in fiscal year 2022, which ended September 30. The transaction is subject to customary regulatory approval and is expected to close by the end of 2022.

07:02 EDT Venus Concept CEO Domenic Serafino departs, Rajiv De Silva succeeds - Venus Concept announced that Rajiv De Silva has been appointed as the Company's CEO and a member of the Board of Directors, effective October 2, 2022. The Company also announced the separation of Domenic Serafino as CEO and Director, effective October 2, 2022. This separation was not the result of any specific disagreement about strategy with management or the Board, inappropriate action, violation of company policy or any accounting irregularity. De Silva currently serves as the Chairman of Covis Pharma, a privately-held, multinational specialty pharmaceutical company, and is a co-founder of Asiri Skincare, a privately-held company focused on topical consumer therapeutic skincare products.

07:01 EDT Calithera Biosciences receives FDA Fast Track designation for CB-228 - Calithera Biosciences announced that the U.S. Food & Drug Administration, FDA, has granted Fast Track designation for the company's investigational mTORC 1/2 inhibitor sapanisertib, CB-228, for the treatment of adult patients with unresectable or metastatic squamous non-small cell lung cancer whose tumors have a mutation in nuclear factor erythroid 2-related factor and who have received prior platinum-based chemotherapy and immune checkpoint inhibitor therapy. "While there have been significant advances in targeted treatments for lung cancer, little progress has been made specifically for patients with squamous lung cancer. In addition, we know that patients with lung cancers that harbor mutations in the NRF2/KEAP1 pathway typically have poorer outcomes than those whose tumors do not have these mutations," said Susan Molineaux, chief executive officer of Calithera. "This Fast Track designation allows for a variety of benefits, including the possibility of priority review of sapanisertib as we seek to provide a first-in-class treatment option that may help address the major unmet need in this patient population."

06:58 EDT Fluor awarded two projects for BASF Zhanjiang Verbund site project in China - Fluor that the company was awarded two reimbursable engineering, procurement and construction management contracts by BASF for the ethylene oxide/ethylene glycol and infrastructure, offsites and utilities packages as part of the company's new Verbund program in Zhanjiang, Guangdong province, China. The contract value to Fluor is more than $2B and was booked in the third quarter of 2022. Fluor's project scope of work for BASF's Zhanjiang Verbund site project consists of two primary packages including the ethylene oxide/ethylene glycol derivative unit and the infrastructure, offsites and utilities scope, comprised of site infrastructure, utility generation and site logistics. Fluor is also performing services as part of the centralized program management team activities. The project will be led by Fluor's Shanghai, China, office.

06:53 EDT Eagle Pharmaceuticals, Enalare announce FDA orphan designation for ENA-001 - Eagle Pharmaceuticals and Enalare Therapeutics announced that the U.S. FDA has granted Orphan Drug Designation to ENA-001 for the treatment of Apnea of Prematurity, a new chemical entity with a novel mechanism of action as a respiratory stimulant. AoP is a development disorder attributed to immaturity of the pulmonary system characterized by either cessation of breathing for more than 20 seconds or cessation of breathing that lasts less than 20 seconds but is accompanied by either bradycardia or hypoxemia. The condition affects approximately 25% of all preterm infants. ENA-001 is designed to work peripherally by inhibiting Big Potassium ion channels in the carotid bodies, which are located in the neck. By inhibiting these channels, ENA-001 utilizes the body's own ventilation control system to stimulate breathing and it does so across multiple causes of respiratory depression.

06:48 EDT Gray Television announces additional voluntary paydown of debt - In light of continued strong cash flow, for the second quarter in a row, Gray Television returned a significant amount of capital to its shareholders during the quarter ending September 30 through cash dividends and repayment of debt. These payments were comprised of a voluntary principal payment of $100M under Gray's 2017 Term Loan B (due 2024), as well as a required principal payment of $3.75M under the 2021 Term Loan D (due 2028), both of which were made on September 30, and $20M of cash dividends to our preferred and common shareholders, which were made earlier in the quarter. Gray continues to anticipate that continued strong cash flow will enable the company to fund additional de-leveraging and cash dividend payments throughout the remainder of this year. The company's financial results for the third quarter have not yet been completed, and that process is ongoing. The company expects to report its financial results for the quarter in approximately four weeks.

06:46 EDT Salunda enters exclusive HaloGuard agreement with Transocean - Salunda has announced an exclusive license agreement with Transocean (RIG) to make, develop and sell HaloGuard, the offshore drilling industry's first safety system that integrates camera and sensor technology with drilling equipment and machine controls. Under this agreement, Salunda holds an exclusive license for all of Transocean's patented zone management methods and technologies in all fields and markets. HaloGuard core functionality is comprised of robotics perception techniques that are responsive to the dynamic environmental conditions of an offshore drilling operation. HaloGuard provides communication and event trigger management between drilling equipment and other systems, such as Salunda's Crew Hawk system. Transocean's patented HaloGuard methodology and technology are licensed exclusively to Salunda. HaloGuard was developed by Nauticus Robotics (KITT) with Salunda. The HaloGuard system is now operational on multiple rigs.

06:37 EDT Macau reports September casino revenue down 49.6% to 2.96B patacas - Macau's gaming bureau reported September gross revenue from games of fortune in the region was down 49.6% year-over-year to 2.962B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO). Reference Link

06:34 EDT CMS Energy upgrades Freedom Compressor Station - Consumers Energy has upgraded a piece of the system supplying natural gas to Michigan homes and businesses. The company finished installing five new units this fall to safely transport natural gas to customers and storage fields as part of a $260M overhaul to the Freedom Compressor Station in Washtenaw County. The project is part of Consumers Energy's Natural Gas Delivery Plan, a 10-year, $11B road map to make its gas system even more safe, reliable, affordable and clean. The new, high-tech compressor units which replaced equipment dating to the 1940s will help Consumers Energy monitor and adjust gas flow more easily and run more efficiently to reduce air emissions.

06:31 EDT Ingersoll-Rand acquires Dosatron International for $90M in cash - Ingersoll Rand has acquired Dosatron International L.L.C. and Dilution Solutions L.L.C. for an all-cash upfront purchase price of approximately $90M, with additional future consideration of up to $15M. Based in Clearwater, Fla., Dosatron International is a technology solutions provider of water powered dosing pumps and systems in North America, with an established presence in attractive end markets including hydroponics, horticulture, animal health, food safety and sanitation, and water treatment. The company has approximately 45 employees and will join Ingersoll Rand's Precision and Science Technologies segment.

06:06 EDT Ensign Group acquires skilled nursing facility in South Carolina - The Ensign Group announced that it acquired the operations of Oak Harbor Healthcare, a 132-bed skilled nursing facility located in Mount Pleasant, South Carolina, and Oak View Health and Rehabilitation, a 190-bed skilled nursing facility located in Conway, South Carolina. The acquisition was effective October 1.

06:05 EDT Ensign Group acquires skilled nursing facility in Arizona - The Ensign Group announced that it acquired the real estate and operations of Fountain Hills Post Acute, a 64-bed skilled nursing facility located in Fountain Hills, Arizona. The real estate was acquired by a subsidiary of Standard Bearer Healthcare REIT, Ensign's captive real estate company, and the acquisition was effective October 1.

06:03 EDT ReneSola closes sale of 70 MW portfolio of solar development projects - ReneSola announced that it closed the sale of a 70 MW portfolio of solar development projects to funds managed by AB CarVal Investors, an alternative investment fund headquartered in Minneapolis, Minnesota. The portfolio consists of three ground-mounted utility scale projects in Pennsylvania located in the broader PJM transmission territory. The projects are being sold at the "Notice to Proceed" stage, and AB CarVal will complete the construction and retain long-term ownership.

06:02 EDT KBR awarded technology contract by Tecnimont - KBR announced that it has been awarded a technology contract by Tecnimont for OCI NV's low-carbon blue ammonia project in the United States. Under the terms of the contract, KBR will supply the technology license, basic engineering design, proprietary equipment and catalyst for the 1.1M ton per annum blue ammonia plant. Targeting completion by 2025, the project will be designed to transition from blue to green ammonia production as green hydrogen becomes available at larger scale in the future. KBR has licensed and designed 252 grassroots ammonia plants since 1944.

05:25 EDT Mesoblast submits new information to FDA in response to remestemcel-L CRL - Mesoblast announced that it has submitted to the FDA substantial new information on clinical and potency assay items identified in the Complete Response Letter, or CRL, received from FDA in September 2020 to the Biologics License Application, or BLA, for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease, or SR-aGVHD. Mesoblast has maintained an active dialog with the FDA since receiving the CRL, and the substantial new information submitted to the Investigational New Drug, or IND, file for remestemcel-L in the treatment of children with SR-aGVHD, as guided by FDA, represents a major milestone in the company's complete response to the FDA. Remestemcel-L has been granted Fast Track Designation and BLA Priority Review from the FDA. Survival outcomes have not improved over the past two decades for children or adults with the most severe forms of SR-aGVHD. The lack of any approved treatments for children under 12 means that there is an urgent need for a therapy that improves the dismal survival outcomes in children.

05:21 EDT Bilibili announces primary listing on Hong Kong stock exchange - Bilibili announced that the company's voluntary conversion of its secondary listing status to primary listing on the Main Board of The Stock Exchange of Hong Kong became effective immediately. Bilibili is now a dual-primary-listed company on the Hong Kong Stock Exchange in Hong Kong and the Nasdaq Global Select Market in the United States.

05:14 EDT Innovative Eyewear announces smart eyewear licensing agreement with Nautica - Innovative Eyewear announced that it has licensed the global lifestyle brand Nautica for smart eyewear. The Nautica smart eyewear collection is expected to launch for Holiday 2022 or soon thereafter.